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ABSTRACT 
Folabomi Abiola Oladosu: Elucidating the Role of MOR-1K in Opioid-Induced Hyperalgesia 
(Under the direction of Andrea G. Nackley) 
 
Opioids commonly used in the treatment of acute and chronic pain have been reported to 
produce a paradoxical opioid-induced hyperalgesia (OIH) in a subset of the population. Recent 
evidence indicates a potential role for MOR-1K, an alternative splice variant of MOR-1, in OIH. 
Unlike its parent receptor, MOR-1K has a genetic association with increased pain sensitivity and 
facilitates cellular excitation upon opioid activation. Because of these properties, we hypothesize that 
MOR-1K contributes to OIH in genetically susceptible individuals. First, using a murine model of 
OIH alongside RNA interference-mediated knockdown and virally-mediated overexpression, we 
established MOR-1K plays a role in OIH development in a strain-specific manner, such that the 
129S6 strain demonstrated an exclusively analgesic pain profile with decreased MOR-1K transcript 
levels, while the CXB7/ByJ strain demonstrated an exclusively hyperalgesic pain profile with 
increased MOR-1K transcript levels. These strain-specific divergences prompted subsequent genetic 
and molecular biologic studies, revealing a functional single nucleotide polymorphism in the MOR-
1K gene locus that is associated with OIH and MOR-1K expression. Additionally, we have 
characterized MOR-1K cellular expression, demonstrating that the splice variant is expression in 
satellite glial cells in the dorsal root ganglion. Together, our findings suggest that MOR-1K is an 
essential contributor to OIH development. With further research, MOR-1K could be exploited as a 
target for development of antagonists that reduce or prevent OIH. 
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Introduction 
 Defining Acute and Chronic Pain 
Pain is a multidimensional sensory and emotional experience that can generally be categorized 
into one of four types(1). Nociceptive pain is an acute response to environmental stimuli that warns of 
potential or actual tissue damage. This type of pain provides is considered adaptive, as it facilitates in 
the avoidance of potentially noxious stimuli. In the event of actual damage, inflammatory and/or 
neuropathic pain may occur. Inflammatory pain occurs in response to damage of tissues or the 
presence of infection. The presence of noxious stimuli (i.e. capsaicin, mustard oil, acid, etc.) or pro-
inflammatory mediators (i.e. Substance P, cytokines, proteases) released from immune cells produce 
a pronociceptive signal accompanied by edema at the site of injury(2). Neuropathic pain occurs in 
response to direct insult of peripheral nerves. This damage, usually caused by lesioning or substantial 
pressure against the nerve, creates increased spontaneous firing, which is associated with unwarranted 
widespread pain, spontaneous sharp or burning pain, and tactile hypersensitivity(3). Inflammatory 
and neuropathic pain typically serve to promote wound healing and repair; however, in many cases 
the pain outlasts the stimulus and becomes chronic. Examples of chronic inflammatory and 
neuropathic pain disorders include complex regional pain syndrome; rheumatoid arthritis; diabetic 
neuropathy; chemotherapy induced neuropathy; and post-surgical neuropathic pain. Unlike three 
aforementioned types of pain, functional or idiopathic pain is characterized by perpetual 
abnormalities in sensory processing that occur in the absence of direct inflammation or nerve damage. 
Chronic pain disorders characterized by functional or idiopathic pain include fibromyalgia, migraine, 
temporomandibular joint disorder, irritable bowel syndrome, and vulvodynia(4). 
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Acute and chronic pain are primarily treated with pharmacologic agents that promote 
analgesia. The principle target of a variety of analgesic drugs including opioids, cannabinergics, and 
anti-depressants is G-protein coupled receptors (GPCRs). Upon activation, GPCRs initiate molecular 
changes resulting in excitation or inhibition of nerve, immune, and glial cells important for the onset 
and maintenance of pain. For example, mu opioid receptors modulate the onset and maintenance of 
pain due to their expression in primary afferent nociceptors, spinal cord, and brain. Given its 
expression in the primary afferents, activation of the mu opioid receptor (MOR-1) quells excitatory 
signaling in pronociceptive Aδ and C fibers. In the spinal cord, MOR-1 activation quells 
pronociceptive signaling via the inhibition of Substance P release and hyperpolarization lamina II 
interneuron. In conjunction with antinociception in the periphery and spinal cord, MOR-1 activation 
in key supraspinal regions affect the perception (i.e. anterior insula, anterior cingulate cortex) and 
descending modulation (i.e. periaqueductal gray, rostral ventromedial medulla) of antinociception(5). 
While the critical role of GPCRs in pain biology and management is well-established, 
reliably effective therapeutics with minimal side-effects are lacking. Inter-individual variability in 
response to a given analgesic is largely due to variation at the genetic level. Of particular interest are 
genetic variants in alternative splice regions that alter protein coding of the mRNA, giving rise to 
proteins which differ in form and function (i.e., alternative splice variants). Chapter 1 will highlight 
the importance of alternative splicing of GPCRs, including MOR-1, in the transmission and 
modulation of pain. Chapters 2 through 4 will then focus on molecular, cellular, and behavioral 
studies that demonstrate a role for MOR-1K, a MOR-1 alternative splice variant, in the development 
of opioid induced hyperalgesia.  
Defining Opioid-induced Hyperalgesia 
Opioids are amongst the most frequently prescribed treatment for acute and chronic pain. As 
of 2012, 259 million prescriptions were written exclusively in the United States(6). The favorability 
of opioids over other types of pain management treatments is due to its potent analgesia. Opioids 
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produce their analgesic effects primarily by targeting MOR-1. MOR-1 is a seven transmembrane 
GPCR, that, upon opioid binding, utilize Gi/o signaling to reduce cyclic adenosine monophosphate 
levels (cAMP) and intra-cellular Ca2+ levels, thus inhibiting pronociceptive signaling(7). MOR-1s are 
located in central, spinal, and peripheral regions where they can modulate the perception, 
transmission, and transduction of pain. Centrally and spinally, MOR-1s are ubiquitously expressed in 
the brain, especially concentrated in somatosensory cortex, the periaqueductal grey, striatum, nucleus 
accumbens, the superficial dorsal horn of the spinal cord(8,9) and in glial cells(10,11). In the 
periphery, MOR-1s are expressed in a variety of cell types: lymphocytes(12,13), dendritic cells(14), 
and endothelial cells(15). Given its vast expression, MOR-1s have the ability to greatly impact pain 
transmission throughout the body.  
Despite its analgesic properties, opioids come with unwanted side effects that complicate pain 
management. These problematic side effects include opioid tolerance, respiratory depression, opioid-
induced constipation, opioid dependence, opioid withdrawal, and addiction(16). Another emerging 
side effect is opioid-induced hyperalgesia (OIH), a paradoxical condition in which opioids produce 
pain. This chapter will review the etiology and known mechanisms of OIH and will also provide the 
foundation for the hypothesis that MOR-1K contributes OIH development in genetically susceptible 
individuals. 
The clinical prevalence of OIH 
Opioid-induced hyperalgesia, or OIH, is defined as increased pain sensitivity following acute 
or chronic opioid administration that is also distinct from the originally reported pain(17). This 
paradoxical condition was first reported in 1986(18); since this initial report, debate still exists over 
the relevance of OIH as a real clinical concern. One point of contention is if OIH is simply another 
presentation of opioid tolerance. Clinical studies have shown that these conditions are indeed 
different. With opioid tolerance, increasing the administered dose to a higher concentration provides 
analgesia that was formerly achieved with a lower concentration. With OIH, however, the 
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administration of an increased amount/or concentration of drug would further exacerbate the patient’s 
reported pain (19,20). 
Although the occurrence of OIH within the general population is unknown, clinical studies 
have revealed three populations that present with OIH: post-surgical patients; former opioid addicts; 
and chronic pain patients. A meta-analysis of twenty seven studies investigating post-operative OIH 
found that high doses of remifentanil administration were associated with increased pain sensitivity 
and that remifentanil-induced pain persisted for at least 24 hours following surgery (21). These data 
demonstrate that acute opioid administration following surgery/injury can produce increased pain 
sensitivity. Similarly, chronic opioid administration also produces increased pain sensitivity, 
specifically in former opioid addicts and in chronic pain patients. When compared to opioid naïve 
participants, both methadone-maintained subjects and opioid-treated chronic pain patients 
demonstrated greater pain responses to thermal cold stimuli(22,23). Furthermore, investigations of 
long-term opioid treatment for chronic pain revealed that OIH manifests differently based on the type 
of chronic pain. For example, within the migraine and IBS populations, OIH can manifest as 
medication overuse headache and narcotic bowel syndrome, respectively (24-26).  
The clinical use of opioids is a critical component of acute and chronic pain management. 
The prevalence of OIH, however, compromises the efficacy of opioid analgesia. If opioids are to 
remain a standard of acute and chronic pain management, it is essential to separate OIH from opioid 
analgesia and prevent its occurrence. In order to achieve this goal, it is necessary to define the 
mechanisms that produce this paradoxical pain.  
The molecular mechanisms of OIH 
The culmination of basic science research suggests that OIH is due to neuroplastic changes in the 
central and peripheral nervous system, ultimately promoting pronociceptive signaling. Despite this 
knowledge, the complete mechanism that causes this opioid-induced sensitization is partially formed. 
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Thus far, the molecular changes related to the central glutamatergic system, the descending 
facilitation system, or the norepinephrine system the have been implicated in OIH.  
Glutamate, one of the most abundant excitatory neurotransmitters, modulates synaptic plasticity 
and long-term potentiation (LTP) via activation of N-methyl-D-aspartate (NMDA) receptor (27). 
Given that LTP is involved in OIH(28), it is no surprise that NMDA receptor also contribute to OIH. 
Following chronic morphine administration in Sprague Dawley rats, Mao and colleagues discovered 
an opioid-induced inhibition in spinal glutamate reuptake transporters, increase synaptic glutamate 
levels(29). A separate study exploring the role of the NMDA receptor in OIH revealed that the co-
administration of s-ketamine or MK-801, both NMDA receptor antagonists, with morphine prevented 
mechanical hyperalgesia and increased NMDAR1 mRNA expression(30,31). S-ketamine, when 
administered preventatively, also blocks remifentanil-induced hyperalgesia clinically(32,33). These 
studies demonstrate that the central glutamatergic system is necessary for OIH development. 
The descending facilitation pathway also contributes to OIH. This pathway, including the 
periaqueductal grey (PAG), rostral ventral medulla (RVM), and the dorsolateral funiculus (DF), 
modulates transmission via the release of endogenous opioids(20). Dysfunction in the descending 
facilitation pathway is known to promote chronic pain conditions and also contributes to OIH. 
Morphine-induced hyperalgesia was found to be blocked via lidocaine injection into RVM(34) or via 
bilateral lesioning of the dorsolateral funiculus(35). Spinal dynorphin, an endogenous opioid peptide 
neurotransmitter involved in descending facilitation, also contribute to the mechanism that drives OIH. 
The pre-emptive intrathecal administration of dynorphin antiserum in rats blocked [D-Ala2, N-
MePhe4, Gly-ol]-enkephalin (DAMGO) induced pain and tolerance(36).  
In addition to glutamatergic activity and descending facilitation, norepinephrine and beta-
adrenergic receptor activity also enable the development of OIH. A preclinical study examining gene 
associations with OIH in mice found a significant correlation between gene ADRB2, which codes for 
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beta 2-adrenergic receptor (β2AR), and morphine-induced hyperalgesia(37). A subsequent clinical 
study found that co-administration of propranolol with remifentanil reduced mechanical hyperalgesia 
in participants(38).  
The aforementioned systems contribute to the central sensitization characteristic of OIH. That 
said, none of these receptors directly bind to opioids, and therefore, cannot be responsible for 
initiating the mechanism that drives OIH. Sticking to the principle of Ockham’s razor, the most likely 
initiator would be a receptor within the mu opioid receptor family, given their high binding affinity 
for opioids. Here, we introduce a likely candidate: a splice variant of the mu opioid receptor, MOR-
1K. 
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CHAPTER 1: The Role of G-Protein Coupled Receptors and Their Alternative Splice 
Variants in Pain Management1 
 
1.1 GPCRs are Relevant for the Treatment of Pain 
Drugs that target GPCRs represent the primary treatment strategy for patients with acute and 
chronic pain; however, there is individual variability in both the efficacy and adverse side effects 
associated with these drugs. These inconsistencies reflects individuals’ variability in alternative 
splicing of pain-relevant GPCRs. Here, this chapter reviews the importance of GPCRs and their 
known splice variants to the management of pain.  
The human genome encodes approximately 800 distinct GPCRs, 70% of which contribute to 
pain-related phenotypes(39). GPCRs interact with a variety of signaling mediators, ranging from 
small molecules to large proteins. Although each receptor has the ability to induce a range of 
functional intracellular changes, all GPCRs possess distinct and evolutionarily conserved architecture. 
Each canonical receptor is comprised of seven transmembrane (7TM) proteins that span the cellular 
membrane. These transmembrane proteins are interconnected by intracellular and extracellular loops 
(Figure 1.1). In addition, there are amino acid chains known as N-terminus and C-terminus tails, 
which are attached to the first and last transmembrane, respectively. As alluded by its name, every 
GPCR is coupled to a G-protein, which acts as a molecular switch to regulate cellular activity.  
  
                                           
1This chapter previously appeared as an article in Mayo Clinic Proceedings. The original citation is as follows: Oladosu F.A., Maixner W., 
and Nackley A.G., “Alternative Splicing of G-Protein Coupled Receptors: Relevance to Pain Management” Mayo Clin Proc 90, no 8. 
(August 2015): 1135-1151. 
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Figure 1.1.  GPCR structure and function. A) A g-protein coupled receptor (GPCR) is composed 
of seven transmembranes (grey) interconnected by three intracellular (orange) and three extracellular 
(purple) loops. On the end of the first and last transmembrane are the N-terminus (blue) and C-
terminus (red), respectively. As its name suggests, a GPCR is bound to a trimeric g-protein composed 
of alpha (α) and beta/gamma (β/γ) subunits. B) When a ligand (black) binds to a GPCR, the 
associated g-protein separates into the α and β/γ subunits. These subunits then stimulate a variety of 
downstream effectors that produce changes in cellular activity (see Table 1). Abbreviations: GPCR = 
G-Protein Coupled Receptor 
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Table 1.1.  Common G-proteins and Their Intracellular Effects 
G protein Effectors Overall Impact 
Gαs activates adenylyl cyclase → ↑ cAMPa cellular excitation (pro-nociceptive) 
Gαq activates PLCβ → ↑ intracellular Ca++ levels cellular excitation (pro-nociceptive)  
Gαi/o inhibits adenylyl cyclase → ↓ cAMP cellular inhibition (anti-nociceptive) 
aAbbreviations: cAMP =  cyclic adenosine monophosphate; Ca++ = calcium;  PLCβ  = phospholipase C β. 
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The resulting structure created by the transmembrane segments and loops provides interactive 
sites where ligands can bind. Ligands that bind to their receptor and initiate cell signaling are referred 
to as agonists. Upon binding, agonists produce a conformational change of the GPCR and subsequent 
uncoupling of the associated g-protein. Once uncoupled, the g-protein separates into two subunits (the 
alpha (α) and beta/gamma (β/γ) subunits), each of which initiates a chain of molecular reactions that 
affect cellular activity(40). Depending on the type of g-protein, the initiated downstream effects can 
promote cellular excitation or inhibition (Table 1.1). In general, agonists that activate pain-relevant 
GPCRs coupled to Gs typically produce pain, while those coupled to Gi typically inhibit pain(39). 
Other ligands, known as antagonists, compete with agonists for the GPCR binding site and impede g-
protein uncoupling and downstream signaling events. Because of their ability to modulate cellular 
activity at each step of the pain pathway, GPCRs represent a popular pharmacologic target for the 
management of clinical pain. In fact, over 60% of commonly prescribed analgesics work by binding 
to GPCRs(40). Table 1.2 provides a summary of these GPCRs (opioid, cannabinoid, adrenergic, and 
serotoninergic receptors) along with their associated g-protein, endogenous ligands, and analgesic 
compounds.  
 
 1
2
Table 1.2.  GPCRs Commonly Targeted for Clinical Pain Management 
GPCR G-protein Endogenous Ligands Prescribed Analgesics Known  Splice  Variant 
   Reuptake Inhibitors  Agonist Antagonist 
Cannabinoid (CB) Receptors   
CB1 Gαi(41)   2-AG 
  Anandamide 
  LPI  
  NADA 
  OAE 
 Nabilone 
THC 
Cannabidiol Yes 
CB2 Gαi(41) Nabilone 
THC 
Cannabidiol Yes 
Adrenergic (AR) Receptors  
α1AR Gαq(42) Epinepherine 
Norepinephrine 
Amitriptyline (NET) 
Despiramine (NET) 
Desvenlafaxine (NET) 
Duloxetine  (NET) 
Levorphanol (MAO) 
Meperidine (NET) 
Nortriptyline (NET) 
Tapentadol (NET) 
Venlafixine (NET) 
 
 
Amitriptyline 
Promethazine 
Nortriptyline 
Trazodone 
Yes 
α2AR Gαi(42) Clonidine 
 
Trazodone No 
 
β1AR Gαs(43)  Atenolol 
Nadolol 
Metoprolol 
No 
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Propanolol 
Timolol  
β2AR Gαs, 
Gαi(43) 
 Nadolol 
Propanolol 
Timolol 
No 
β3AR Gαs(43)  Nadolol  
Propanolol 
Timolol 
Yes 
Serotonin (5-HT) Receptors  
5-HT1 Gαi(44) Serotonin Amitriptyline (SERT) 
Despiramine (SERT) 
Desvenlafaxine (SERT) 
Duloxetine (SERT) 
Levorphanol (MAO)  
Nortriptyline (SERT) 
Trazodone (SERT) 
Venlafaxine (SERT) 
Almotriptan 
Dihydroergotamine 
Eletriptan 
Frovatriptan 
Naratriptan 
Rizatriptan 
Sumatriptan 
Zolmitriptan 
Trazodone No 
5-HT2 Gαq(44) Dihydroergotamine Amitriptyline Yes 
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Methylergometrine Nortriptyline 
Promethazine 
Trazodone 
5-HT4 Gαs(44) Mosapride 
 
 Yes 
5-HT6 Gαs(44)  Amitriptyline 
Nortriptyline 
Trazodone 
Yes 
5-HT7 Gαs(44)  Amitriptyline 
Trazodone  
Yes 
Mu-Opioid Receptor  
 MOR-1a Gαi(45)   α-endorphin 
  β-endorphin 
  γ-endorphin 
  Alfentanil 
Buprenorphine 
Codeine 
Fentanyl 
Hydrocodone 
Hydromorphone 
Levorphanol 
Naloxone 
Naltrexone 
Yes 
 1
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Meperidine 
Methadone 
Morphine 
Oxycodone 
Oxymorphone 
Remifentanil 
Sufentanil 
Tapentadol 
Tramadol 
Abbreviations: 2-AG = 2-Arachidonoylglycerol; 5-HT = Serotonin; CB = Cannabinoid; LPI = Lysophosphatidylinositol; MAO = Monoamine Oxidase; MOR-1 = Mu Opioid 
Receptor NADA = N-Arachidonoyl Dopamine; NET = Norepinephrine Transporter; OAE = O-Arachidonoyl ethanolamine; SERT = Serotonin Transporter; THC = 
Tetrahydrocannabinol; αAR = Alpha adrenergic receptor; βAR = Beta adrenergic receptor 
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Cannabinoid receptors share similar signaling properties with MOR-1, making them 
attractive targets for clinical pain management. There are two cannabinoid (CB) receptor subtypes, 
CB1 and CB2, both of which couple to Gαi. CB receptors play a significant role in promoting analgesia 
in response to endocannabinoids such as 2-Arachidonoylglycerol (2-AG), and anandamide. 
Commercially available CB agonists such as nabilone and tetrahydrocannabidol, which bind to both 
CB subtypes, are used to treat fibromyalgia and neuropathic pain(46). 
Adrenergic receptors, which mediate the physiological responses to epinephrine (Epi) and 
norepinephrine (NE), represent another frequently targeted class of GPCRs. The adrenergic 
superfamily includes three subtypes respectively of α1ARs (α1AAR, α1BAR, α1DAR), α2ARs (α2AAR, 
α2BAR, α2CAR), and βARs (β1ARs, β2ARs, β3ARs). The α2AR couples to Gαi and promotes analgesia 
via cellular inhibition. Hence α2AR agonists such as trazodone are used to promote analgesia. In 
contrast, α1AR, which is coupled to Gαq, facilitates cellular excitation of pronociceptive neurons, 
resulting in increased pain signaling. The βARs also facilitate pain signaling via Gαs signaling. To 
attenuate their excitatory contributions, α1AR and βARs are commonly used to treat a range of 
chronic pain disorders such as migraine, neuropathic pain, and fibromyalgia. 
Serotonin receptors, which mediate physiological responses to the monoamine serotonin (5-
HT) play an important role in pain management(44). The serotonin superfamily is quite large, 
including seven general members: 5-HT1 (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), 5-HT2 (5-HT2A, 
5-HT2B, 5-HT2C), 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. With the exception of the 5-HT3 receptor, a 
ligand-gated ion channel, all 5-HT receptors are GPCRs. The effects of the 5-HT receptor family on 
pain are heavily dependent upon the receptor subtype. Triptans target Gαi-coupled 5-HT1 receptors, 
which promote analgesia via cellular inhibition, and normalize vascular changes associated with 
migraine headache(47). Antidepressants promote chronic synaptic serotonin release that causes the 
downregulation of Gαq coupled 5-HT2 receptors, thus attenuating their excitatory contributions to pain 
signaling.  5-HT antagonists that target 5-HT4 receptors in the central nervous system and the 
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gastrointestinal (GI) tract are used in the treatment of migraine(48) and IBS(49). Meanwhile, the net 
effect of 5-HT7 activation on pain is highly dependent on the location of the receptor. Activation of 5-
HT7 receptors on peripheral nerve terminals produces pain(50,51), while activation in midbrain 
structures such as the periaqueductal gray alleviates pain associated with nerve injury(52). 
Finally, opioid receptors are among the most well known GPCRs that regulate the 
transmission and perception of pain. There are four opioid receptor subtypes, including: the mu 
opioid receptor (MOR-1), the delta opioid receptor, the kappa opioid receptor, and the nociceptin 
receptor (ORL-1). Of these subtypes, MOR-1 is the classic receptor responsible for analgesic 
responses to endogenous endorphins as well as exogenous drugs. Upon agonist binding to MOR-1, its 
associated Gαi protein is activated and produces cellular inhibition of pronociceptive neurons(7). For 
this reason, opioids are used in the management of acute pain (such as that associated with surgery) as 
well as chronic pain disorders such as low back pain, extremity pain, and osteoarthritis(53). Opioid 
antagonists, usually co-administered with opioid agonists to reduce the development of unwanted 
opioid side effects, are also capable of producing analgesia independently of MOR-1(54). 
While these conventional therapeutics are able to alleviate pain, their efficacy is limited to a 
subset of the population(55). Additionally, their use is constrained by adverse side effects, such as 
altered mental state, nausea, constipation, sedation, and life-threatening respiratory depression. 
Variability in patient response and side-effect profiles is, in part, due to variability in alternative 
splicing of GPCRs expressed in tissues that regulate pain processing. By expanding our 
understanding of GPCR alternative splice variants and their associated pharmacodynamic responses, 
we will be able to better predict patient-centered treatment outcomes. 
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1.2 The Impact of Alternative Splicing on GPCR Signaling 
1.2.1 Alternative splicing adds to the diversity of GPCR signaling  
Alternative splicing is an important mechanism of gene regulation, affecting approximately 
90% of all genes within the human genome(56). A single gene is able to generate exponential protein 
coding capabilities via alternative splicing. Prior to alternative splicing, a gene is first transcribed into 
precursor messenger ribonucleic acid (pre-mRNA). The pre-mRNA sequence contains short protein 
coding regions known as exons.  Interspersed between the exons are longer non-coding regions 
known as introns (Figure 1.2). Before the sequence can be translated to produce protein, the introns 
and alternative exons within pre-mRNA are removed, or spliced, and the constitutive exons are 
brought together, resulting in the canonical mRNA transcript ready for protein synthesis. When 
alternative splicing occurs, however, the pre-mRNA is edited such that constitutive exons are 
removed from, or introns are retained, in the final mRNA transcript. The most common type of 
alternative splicing within the human genome is exon skipping(57). Here, constitutive exons are 
excluded from the final mRNA transcript. Another common type of alternative splicing is splice site 
selection, in which the portion of an exon is spliced out due the presence of a nucleotide sequence that 
facilitates splicing activity(57). Intron retention is another type of alternative splicing in which an 
intron remains in the final mRNA transcript. Each type of alternative splicing will render an mRNA 
transcript and corresponding protein that is structurally different than the canonical protein produced 
from the standard template (Figure 1.3).  
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Figure 1.2. Different types of alternative splicing. The most common type of alternative splicing in 
animals is A) exon skipping, in which a constitutive exon is spliced from the final mRNA transcript. 
Alternative B) 3’ and C) 5’ splice sites provide additional junctions within an exon, resulting in 
partial splicing of the exonic mRNA sequence. D) Intron retention is a rare type of alternative splicing 
that occurs when an intron remains within the final mRNA transcript. Abbreviations: mRNA = 
Messenger Ribonucleic Acid 
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Figure 1.3. Structural variations in GPCRs as a result of alternative splicing. Exons within the 
mRNA transcript serve as coding regions for specific sections of protein. Alternative splicing events 
that change or remove exonic sequences can produce GPCR splice variants with corresponding 
changes in protein composition and/or structure. A) For example, splicing events that lead to 
alterations in exon 1 can yield GPCRs with truncated N-termini that affect ligand binding, while 
events that lead to alterations in exon 4 can yield GPCRs with truncated C-termini that affect g-
protein coupling and signaling. B) Splicing events can also lead to skipping of an exon that codes for 
an unit of the GPCR, such as a transmembrane, thus yielding a truncated GPCR lacking the encoded 
section, such as a 6 transmembrane (6TM) splice variant. Abbreviations: GPCR = G-Protein Coupled 
Receptor; TM = Transmembrane 
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Accumulating evidence suggests that alternative splicing significantly adds to the functional 
diversity of the human genome and that variations in these processes produce pathological states(58). 
The presence of multiple GPCR splice variants allows for essential, precisely regulated differences in 
expression (e.g., tissue-specific expression)(59), as well as in agonist binding(60), agonist-induced 
internalization21, and intracellular signaling dynamics(61,62). Some alternative splice variants even 
display functional characteristics opposite to the canonical form(63-65) (Table 1.3). Polymorphisms 
that alter the ratio of functionally distinct protein isoforms through alternative splicing may produce 
changes in the direction of pain-relevant GPCR pharmacodynamics (e.g. coupling to stimulatory vs. 
inhibitory G protein effector systems), yet remain understudied. A PubMed search of “alternative 
splicing pain” yields only 87 relevant original research articles. Most are focused on ion channels 
such as voltage-gated calcium channels(66) and transient receptor potential channels(67,68), with 
only 12 articles focusing on GPCRs. This is an important area of study as identification of GPCR 
splice variants differentially expressed in individuals with altered pain perception and/or analgesic 
responses will help elucidate novel targets for the development of individualized treatment strategies. 
1.2.2 Alternative splicing creates functional GPCR variants 
Examples of alternative splice variants of pain-relevant GPCRs that exhibit diversity in 
expression and signaling profiles include the aforementioned cannabinoid receptors, adrenergic 
receptors, serotonin receptors, and opioid receptors. Accumulating evidence from in vitro, pre-clinical, 
and clinical studies suggests that alternative splicing of these and other GPCR transcripts adds 
additional layers of complexity to GPCR signaling and pharmacodynamics responses. 
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Table 1.3. Signaling, Tissue Distribution, and Function of Known GPCR Splice Variants.  
Receptor 
Variants 
G-protein Tissue Distribution Functional Characteristics 
Cannabinoid Receptors 
CB1 
 
N-term 
variants 
CB1a 
CB1b 
Gαi(41) 
 
 
 
brain, sc, DRG > pituitary > heart, lung, uterus, testis, 
spleen, tonsils(69) 
 
 
similar distribution to CB1+ kidney(70,71) 
fetal brain > GI tract, uterus, muscle > adult brain(70) 
 
 
 
↓ agonist binding, ↓ GTPᵞ S activity(70) 
↓ agonist binding, ↓ GTPᵞ S activity(70) 
CB2 
 
N-term 
variants 
CB2A 
CB2B 
Gαi(41)  
 
immune cells/tissues > glia and macrophages in 
brain/sc(69,72-74) 
 
 
testis > spleen, leukocytes > brain(75) 
spleen > leukocytes(75) 
 
 
 
? 
? 
Adrenergic Receptors 
α1A 
 
C-term 
variants 
Gαq(42)  
 
 
Gαi(43) 
liver, heart, brain > prostate, kidney, bladder(42) 
 
 
liver, heart > prostrate, kidney(76,77) 
 
 
pharmacology similar to α1A(43,76,77,79) 
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α1A-2 
α1A-3 
α1A-4 
α1A-5 
 
6TM variants 
(-TM7) 
α1A-6 
α1A-7 
α1A-8 
α1A-9 
α1A-10 
α1A-11 
α1A-12 
α1A-13 
α1A-14 
α1A-15 
α1A-16 
Gαi(43) 
Gαi(43) 
liver > heart, prostrate (absent in kidney)(76,77) 
liver, heart > prostrate, (absent in kidney)(76,77) 
 
 
liver, heart, hippocampus, and prostate; expressed 
intracellularly(78) 
 
 
 
 
impair α1A binding & cell surface expression(78) 
α1B 
 
6TM variant (-
Gαq(42) 
 
 
liver, heart, brain (including cortex) (42) 
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TM7) 
α1B-2 
 expressed in hippocampus, but absent in cortex(80) ? 
β3 
 
C-term 
variants 
β3a (mouse) 
β3b (mouse) 
Gαs, Gαi(81,82) 
 
 
Gαs(43,83) 
Gαs, Gαi(43,83) 
fat, immune cells/tissues > GI tract, DRG(81,84) 
 
 
fat > ileum > brain(85) 
brain > fat, ileum(85) 
 
 
 
? 
? 
Serotonin Receptors 
5-HT2A 
 
6TM variant (-
TM4) 
5-HT2A-tr 
Gαq(44) 
 
 
 
cortex, hippocampus, brainstem, olfactory > basal ganglia, 
limbic(44) 
 
 
hippocampus, caudate, corpus collosum, amygdala, 
substania nigra(86)  
 
 
 
impaired 5-HT-induced Ca++ signaling(86) 
5-HT2C 
 
6TM variant (-
TM4) 
5-HT2CT 
 
Gαq(44) choroid plexus, striatum, hippocampus, hypothalamus, 
olfactory, sc(44,87) 
 
 
choroid plexus, striatum, hippocampus, hypothalamus, 
olfactory, sc(87) 
 
 
 
impaired 5-HT ligand binding(87) 
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C-term variant 
5-HT2AC-R-
COOH∆ 
 
 
sc, cortex, cerebellum, medulla, caudate, amygdala, 
corpus collosum(88) 
impaired 5-HT ligand binding(88) 
5-HT4 
 
C-term 
variants 
5-HT4a 
5-HT4b 
5-HT4c 
5-HT4d 
5-HT4e 
5-HT4f 
5-HT4g 
5-HT4i 
5-HT4n 
 
2nd EL loop 
variant 
5-HT4h 
Gαs(44) 
 
 
Gαs(89) 
Gαs, Gαi(89,90) 
Gαs(89) 
Gαs(89) 
Gαs(91) 
Gαs(92) 
Gαs(93) 
Gαs(94) 
Gαs(95) 
 
 
Gαs(92) 
intestine > brain > pit > uterus, testis > spleen > heart, 
kidney, lung, sc(96) 
 
 
intestine, brain > pit > uterus, testis > heart > spleen, lung, 
sc(96) 
intestine, brain > pit > uterus > heart, spleen, lung, sc(96)  
intestine > pit > brain > uterus, testis, heart, spleen, sc(96) 
ileum, colon, but absent in brain(95,97)  
brain > testis > sc > intestine, pit, heart, prostate ileum, 
colon(97) 
brain, ileum, colon(97) 
brain, heart, ileum, colon(97) 
brain, ileum, colon, heart(97) 
brain, heart, esophagus(97) 
 
 
 
 
 
↑ constitutive AC activity, ↑ isomerization, ↓ agonist 
internalization(98,99) 
↑ constitutive AC activity(89) 
↑ constitutive AC activity(89) 
20-fold ↑ in agonist-induced cAMP activity(100) 
↑ constitutive AC activity(91) 
? 
? 
↑ constitutive AC activity(101)  
 
 
 
antagonist GR113808 acts as partial agonist(92) 
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GI tract(92) 
5-HT6 
 
6TM variant (-
TM4) 
5-HT6-tr 
Gαs (44) 
 
 
cortex, hippocampus, olfactory, striatum, amygdala, 
accumbens(44) 
 
 
cortex, hippocampus, cerebellum, thalamus, substantia 
nigra, caudate(102) 
 
 
 
impaired binding to 5-HT and LSD(102) 
5-HT7 
 
C-term 
variants 
5-HT7a  
5-HT7b  
5-HT7d 
Gαs(44) 
 
 
Gαs(103) 
Gαs(104) 
Gαs(104) 
brain, heart, GI tract, muscle, kidney, astrocytoma, 
glia(105,106)  
 
 
brain, heart, GI tract, spleen, lung, astrocytoma, 
glia(103,105,106) 
brain, heart, GI tract, spleen, lung, astrocytoma, glia(104)-
(105,106) 
heart, GI tract, ovary, testis, spleen, lung, 
astrocytoma(105) 
 
 
 
? 
↑ constitutive AC activity(104) 
exhibit agonist-independent internalization(107) 
Opioid Receptors 
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MOR-1 
C-term 
variants  
MOR-1A 
MOR-1B 
MOR-1C 
MOR-1D 
MOR-1E 
MOR-1F 
MOR-1O 
MOR-1P 
MOR-1U 
MOR-1V 
MOR-1W 
MOR-1X 
MOR-1Y 
 
N-term 
variants  
MOR-1G 
MOR-1H 
Gαi(45) 
 
 
 
 
 
Gαi(108) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
brain, spinal cord > adrenal gland > small intestine(109) 
 
brain(110) 
brain(110) 
brain(110); agonist-induced reduction(111) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
 
 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
 
 
OP binding  analgesia(113) 
OP binding  analgesia(113) 
OP binding  analgesia(113) 
OP induced itch(108)  
OP binding  analgesia(113) 
OP binding  analgesia(113) 
? 
? 
? 
? 
? 
? 
OP binding  analgesia(114) 
 
 
Novel opioid binding(115) 
OP binding  analgesia(116) 
OP binding  analgesia(116) 
OP binding  analgesia(116)  
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MOR-1I 
MOR-1J 
MOR-1K 
MOR-1L 
MOR-1M 
MOR-1N 
 
Single TM 
variants  
MOR-1Q 
MOR-1R 
MOR-1S 
MOR-1T 
MOR-1Z 
MOR-1SV1 
MOR-1SV2 
 
Gαs(65) 
 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
 
 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain(110) 
brain (human neuroblastoma cell line)(112) 
brain (human neuroblastoma cell line)(112) 
contributes to OIH 
OP binding  analgesia(116)  
? 
? 
 
 
? 
Stabilization of MOR-1(117) 
Stabilization of MOR-1(117) 
? 
? 
? 
? 
Abbreviations: 5-HT = serotonin; AC = adenylyl cyclase; N-term = amino terminus; Ca++ = calcium; C-term = carboxyl terminus; cAMP = cyclic adenosine 
monophosphate; EL = extracellular loop; GI = gastrointestinal; LSD = lysergic acid diethylamide; OP = opioid; sc = spinal cord; SP = Substance P; TM = 
transmembrane  
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Cannabinoid receptors 
Both the CB1 and CB2 receptors undergo alternative splicing to yield variants differing at 
their N-terminal region. The CB1a variant is truncated by 61 amino acids, with the first 28 amino acids 
completely different from the canonical CB1(71). While its tissue distribution largely overlaps with 
that of CB1, CB1a exhibits decreased agonist binding and activity, which might be due to a lack of two 
glycosylation sites typically important for signal transduction(118). The CB1b variant lacks the first 33 
N-terminus amino acids and although it overlaps with CB1 in a number of tissues, its abundant 
expression in fetal brain suggests it may play an important role in development(70). Similar to CB1a, 
CB1b exhibits decreased agonist binding and activity.  
The CB2 variants are generated through the use of alternate promoters located upstream of the 
major coding exon 3(75). The gene CB2A is initiated from the more distal promoter and includes 
exons 1a and 1b spliced to exon 3, while CB2B is initiated from the more proximal promoter and 
includes exon 2 spliced to exon 3. The CB2A variant is predominantly expressed in testes and at lower 
levels in spleen and brain. In contrast, the CB2B variant is predominantly expressed in spleen with 
very low expression in brain and no expression in testes. These tissue-specific distribution patterns 
may indicate specialized roles for the different splice variants with respect to pain modulation, 
immune response, and spermatogenesis.  
Adrenergic receptors 
Adrenergic receptors play a key role in pain processing as well as cognition and 
cardiovascular function. While α2ARs, β1ARs, and β2ARs are highly relevant to the modulation of 
pain by endogenous and exogenous agonists, the genes encoding these receptors are intronless and 
not subject to alternative splicing. Among the remaining adrenergic receptors, the α1AAR subtype has 
best most extensively studied with respect to alternative splicing.  
The human α1AAR gene locus is comprised of over 8 exons and codes for 15 known splice 
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variants(119). The canonical receptor is generated through splicing exon 1 (coding for the N-terminus 
and transmembranes [TM] 1 to 6) together with exon 2 (coding for TM7 and the C-terminus). Four C-
terminus splice variants (α1A-2, α1A-3, α1A-4, α1A-5) have been identified that are generated through the 
use of additional acceptor sites at varying locations within, and distal to, exon 2. The α1A-2, α1A-3, and 
α1A-4 variants exhibit ligand binding properties and tissue distribution profiles similar to α1AAR, 
although α1A-3 and α1A-4 are absent in kidney(76-79). In contrast to α1AAR that couples to Gαq, these 
variants couple to Gαi so as to inhibit AC activity(43). This diversity in α1AAR signaling may 
contribute to differential responses to α1AR antagonists used in the treatment of pain. 
In addition, eleven 6TM variants (α1A-6, α1A-7, α1A-8… α1A-16) have been identified that are 
generated through exon skipping. These variants lack TM7 and their C-terminal tails are located 
extracellularly(78). The truncated 6TM variants are expressed in similar tissues as α1AAR, but are 
localized exclusively within the cell and unable to bind α1AR agonists or directly mediate signal 
transduction. The 6TM variants do, however, impair α1AAR ligand binding and trafficking to the cell 
surface. Thus, α1AAR 6TM variants likely play a significant physiological role by modifying the 
function and expression of their parent 7TM receptors.  
One α1BAR splice variant has also been identified in human brain(80). The α1BAR protein is 
generated through splicing of exons 1 and 2. In contrast to the canonical receptor, the α1B-2AR 
includes an immediately adjacent sequence following exon 1 in its coding sequence and excludes 
exon 2 that codes for TM7. Tseng-Crank and colleagues also identified low levels of a truncated 
α1DAR transcript, however the result was inconclusive and naturally occurring α1DAR variants were 
not observed(80). More work is required to determine the potential functional role of α1BAR and 
α1DAR variants.  
The β3AR is primarily known for its ability to regulate energy metabolism and 
thermogenesis(80), though evidence for its ability to promote functional and neuropathic pain is 
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emerging (83,85,120). The gene encoding β3AR undergoes alternative splicing within the coding 
region to yield two C-terminal splice variants differing with respect to tissue expression, g-protein 
signaling profiles, and regulatory properties(79,86,121). The β3AAR and β3BAR splice variants 
contain completely unique terminal chains that are 13 and 17 amino acids long, respectively. The 
β3AAR is primarily enriched in fat tissue and couples exclusively to Gαs, while the β3BAR is primarily 
enriched in brain and couples to both Gαs and Gαi. In addition, the β3AAR exhibits increased agonist-
induced extracellular acidification, a measure of cAMP-independent cellular activity. Their unique 
tissue distribution and signaling profiles, together with the known functional role of β3ARs, could 
indicate that β3AARs play a greater role in lipolysis/thermogenesis and that β3BAR in brain mediate 
pain. While these studies were conducted in mouse, it is important to note that the human β3AR 
contains a significant number of genetic variants that are predicted to regulate alternative 
splicing(87,88).    
Serotonin receptors  
Serotonin receptors play a key role in pain processing as well as mood and GI function(44). 
Of the 5-HT1 (A, B, D-F), 5-HT2 (A-C), 5-HT4, 5-HT5, 5-HT6, and 5-HT7 GPCR family members, the 
5-HT2A, 5-HT2C, 5-HT4, 5-HT6, and 5-HT7 receptors are known to undergo alternative splicing. 
The human 5-HT2 receptor subtypes (5-HT2A, 5-HT2B, and 5-HT2C) couple to Gαq proteins to 
promote the transient release of intracellular calcium. One truncated splice variant of 5-HT2A (5-HT2A-
tr) has been identified that utilizes alternate splice donor and acceptor sites to yield a 3TM receptor 
with 57 unique amino acids in the C-terminal region(86). The 5-HT2A-tr is co-expressed with 5-HT2A 
in most brain tissues, however is unable to couple to the calcium pathway. Two truncated splice 
variants of 5-HT2C (5-HT2CT and 5-HT2C-R-COOH∆) have also been identified. Similar to 5-HT2A-tr, the 5-
HT2CT variant utilizes alternate splice donor and acceptor sites to yield a 3TM receptor with 19 unique 
amino acids in the C-terminal region(87). The 5-HT2C-R-COOH∆ variant retains an extra 90 nucleotides 
from intron 5 in the TM4 splice site, resulting in a 3TM receptor with a short C-terminus(88). 
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Compared to the canonical 5-HT2C receptor, the truncated variants exhibit similar expression patterns 
but have impaired 5-HT ligand binding and g-protein coupling(87,88). While the relative importance 
of these truncated 5-HT2 splice variants in humans remains unknown, they are conserved in rat and 
mouse(88) where their expression levels increase following nerve injury(122).      
The 5-HT4 receptor couples preferentially to Gαs and, while widely expressed, the highest 
levels are found in intestine(96). Agonists targeting 5-HT4 are beneficial in alleviating abdominal pain 
associated with irritable bowel syndrome. Of all the 5-HT receptors, 5-HT4 possesses the greatest 
diversity in alternative splicing. At least ten splice variants have been identified that vary with respect 
to their tissue distribution and function. Nine C-terminus variants (5-HT4a, 5-HT4b, 5-HT4c, 5-HT4d, 5-
HT4e, 5-HT4f, 5-HT4g, 5-HT4i, 5-HT4n) have been identified that are identical up to amino acid Leu358, 
after which they vary in sequence and length(97). Additionally, one variant (5-HT4h) has been 
identified that includes exon h coding for 14 additional amino acids in the second extracellular 
loop(92). The 5-HT4a, 5-HT4b, 5-HT4c, and 5-HT4e variants are expressed in most tissues, with 
distribution patterns similar to the canonical form(96,97). In contrast, the 5-HT4f variant is found in 
the brain and GI tract, but absent in the heart and other tissues22. Meanwhile, the 5-HT4d and 5-HT4h 
variants are expressed exclusively in the GI tract(92,94,97). While all of the 5-HT4 splice variants 
display typical ligand binding properties, some show notable functional differences. Both of the GI-
specific 5-HT4d and 5-HT4h variants have a tendency to recognize 5-HT antagonists as partial 
agonists(92,100). Furthermore, the 5-HT4d variant exhibits a remarkable 20-fold increase in cAMP 
formation following application of the 5-HT4 agonist renzapride(100). The 5-HT4b variant is unique in 
its able to couple to Gαi as well as Gαs proteins, suggesting its diverse signaling capabilities in the GI 
tract, brain, and other tissues(90). In the absence of ligand binding, the majority of C-terminus 
variants exhibits heightened constitutive AC activity(89,91,95,98-100). The ability of GPCRs to 
increase basal AC activity has been previously reported and can result in physiological functions of 
the receptor that are largely independent of endogenous ligands or exogenous drugs(123).  
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Collectively, these studies illustrate the high degree of tissue and signaling specificity for a number of 
5-HT4 splice variants that may be represent attractive targets for the development of new more 
selective drugs for the treatment of irritable bowel syndrome among other conditions. 
The 5-HT6 receptor is unique in that it is expressed almost exclusively in the central nervous 
system(44). A 3TM splice variant of 5-HT6 (5-HT6-tr) has been identified in brain that is generated 
through different splice donor and acceptor sites(102). The corresponding receptor includes the TM1-
3 and 10 unique amino acids in its C-terminus. In contrast to 5-HT6, the expression of 5-HT6-tr is 
limited to substantia nigra and caudate. The 5-HT6-tr receptor is able to translocate to the membrane, 
yet unable to bind serotonin. This splice variant may have a yet-to-be-determined function or be 
indicative of abnormalities due to pathologic state. 
The 5-HT7 receptor is expressed on primary afferent nociceptors, as well as in pain-relevant 
brain regions where it couples to Gαs to mediate the transmission and modulation of pain. Three splice 
variants of 5-HT7 (5-HT7a, 5-HT7b, 5-HT7d) have been identified that are all generated through 
alternative splicing of the second intron located near the C-terminal coding region. The 5-HT7a and 5-
HT7b variants have tissue expression profiles and functional characteristics similar to the canonical 
receptor, though 5-HT7b has been shown to exhibit significantly higher constitutive AC activity when 
expressed in stable cell lines{Krobert:2002du}. The 5-HT7d variant is predominantly expressed in 
smooth muscle tissues such as the heart and GI tract(104) and displays unique functional 
characteristics. Compared to the canonical 5-HT7 receptor and the 5-HT7a and 5-HT7b variants, the 5-
HT7d variant displays agonist-independent internalization (even in the presence of antagonist) and 
associated reductions in agonist-induced AC activity(107). It has been suggested that differences in 
the functional characteristics of 5-HT7 variants is due to specific features of their carboxyl tails, 
leading to differential interactions with protein partners that mediate their activity, trafficking, and/or 
internalization(107,124).  
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Opioid receptors 
The pharmacologic manipulation of the mu opioid receptor is an essential component of 
clinical pain treatment. Although the signaling characteristics of MOR-1 are well established, we are 
just beginning to understand the complex nature of genetic variants that contribute to alternative 
splicing. At least 20 MOR-1 splice variants have been identified in mouse and human genomes(61), 
suggesting an array of potentially functional consequences that may occur with opioid administration.  
Pre-clinical studies within the past 15 years have begun to reveal the functional properties of 
specific MOR-1 splice variants. Pasternak and coworkers provide evidence that the expression of 
MOR-1 splice variants represent compensatory responses to chronic opioid administration that 
stabilize or diminish the development of tolerance(125). Additional studies investigating the 
functional characteristics of MOR-1 splice variants provide evidence that a set of these receptors 
promote opioid analgesia by providing exclusive binding sites for different opioids. Transgenic mice 
lacking exon 11, an exon that provides an alternative promoter region for the MOR transcript, 
demonstrated substantial reductions in the analgesic efficacies of heroin, fentanyl, and the morphine 
metabolite morphine-6β-glucuronide(60), suggesting that exon-11 containing variants play a critical 
role in opioid analgesia. Exon 11-containing splice variants also mediate the analgesic effects of 
iodobenzoylnaltrexamide (IBNtxA), a novel synthetic opioid that produces ten times the analgesic 
efficacy of morphine without producing respiratory distress, dependence, tolerance, or GI distress in 
rodents(111,115,126). MOR-1 splice variants also promote analgesia by enhancing canonical receptor 
function. Single-transmembrane splice variants MOR-1R and MOR-1S structurally enhance MOR-1 
function by stabilizing the canonical 7TM receptor at the cellular membrane(117).  
 Other studies have shown that the presentation of some unwanted side effects are due to the 
activation of MOR-1 splice variants. For example, Liu and colleagues have demonstrated that because 
of its distinct C-terminus, the splice variant MOR-1D dimerizes with the gastrin-releasing peptide 
receptor in the mouse spinal cord to produce opioid-induced itch(108). Another splice variant known 
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as MOR-1K, a truncated receptor lacking the N-terminus and first transmembrane, has been 
implicated in the paradoxical increase in pain sensitivity known as opioid-induced hyperalgesia (OIH). 
In contrast to MOR-1 which typically couples to Gαi, MOR-1K couples to Gαs to activate adenylyl 
cyclase (AC) and increase intracellular calcium, thus engaging pro-nociceptive signaling events that 
likely drive OIH(65). A subsequent preclinical study in mice revealed that genetic knockdown of 
MOR-1K hindered the development of OIH and unmasked opioid analgesia(127). The relationship 
between MOR-1K and OIH is further discussed throughout the remainder of the manuscript. 
Conclusion 
 G-protein coupled receptors play a major role in modulating the activity of a chorus of cells 
involved in the transmission, modulation and perception of pain. For this reason, GPCRs are the 
primary target of many pharmacologic interventions used in the management of acute and chronic 
pain. Nonetheless, the use of these medications is limited due to variability in analgesic efficacy and 
side effect profiles. These limitations are partly attributed to genetic differences that influence 
alternative splicing of pain-relevant GPCRs. The functional importance and implications of the 
diversity of GPCRs in contributing to the pathophysiology of clinical pain is just beginning to emerge. 
More research, especially in the clinical arena, is necessary to further investigate the functions of 
specific GPCR splice variants, as well as the dynamic interactions between multiple variants of the 
same canonical receptor, within the context of pain. This line of inquiry will evolve our understanding 
of pain mechanisms and inform the design of new and clinically useful drugs that target specific 
alternative splice variants altered in a subset of patients.  
In the next chapter, I provide experimental evidence that points to the mu opioid splice 
variant MOR-1K as a target for the development of pharmacologic therapies that can be used to 
manage pain without producing paradoxical opioid induced hyperalgesia  
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CHAPTER 2: MOR-1K Contributes to OIH in Genetically Susceptible Mice 2 
2.1. Introduction 
Accumulating evidence indicates that MOR-1K, a functional splice variant of the canonical 
mu opioid receptor (MOR-1), may contribute to the emergence of OIH.  MOR-1K is a truncated six 
transmembrane G-protein coupled receptor (GPCR) lacking a N-terminus transmembrane due to the 
absence of exon 1 within its mRNA transcript (61). Replacing exon 1 are exon 11, which provides an 
alternative translation start site in several MOR-1 splice variants, and exon 13, which is unique to the 
MOR-1K transcript. The MOR-1 transcript, which encompasses exons that encode for MOR-1K, is 
highly conserved across species, with a 91% nucleotide sequence homology between human and 
mouse. Results from a human genetic association study demonstrated that a single nucleotide 
polymorphism within exon 13 of the human MOR-1K transcript is associated with increased pain 
sensitivity and blunted morphine efficacy (128). Subsequent in vitro studies demonstrated that MOR-
1K exhibits signaling properties distinct from its parent receptor MOR-1. MOR-1 utilizes Gi/o protein 
to inhibit cyclic adenosine monophosphate (cAMP) levels and intracellular calcium levels to produce 
cellular inhibition of pronociceptive cells. In contrast, MOR-1K couples to Gs protein, leading to 
increased cAMP production and intracellular calcium levels, thus promoting cellular excitation (65). 
Previous studies have shown that Gs-dependent increases in intracellular calcium via cAMP 
production and protein kinase A activation play a critical role in central sensitization (129) and the 
development of inflammatory, neuropathic, and functional pain (130). The utilization of Gs signaling 
                                           
2 This chapter previously appeared as an article in PLoS ONE. The original citation is as follows: Oladosu F.A., Conrad M.S., O’Buckley 
S.C., Rashid N.U., Slade G.D., and Nackley A.G., “Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced 
Hyperalgesia” PLoS ONE 10, no 8. (August 2015): e0135711 
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by MOR-1K suggests that the receptor may also contribute to central sensitization associated with 
OIH. 
Given the receptor’s genetic association with increased pain sensitivity and its excitatory 
signaling profile, we hypothesize MOR-1K may contribute to OIH in genetically susceptible 
individuals. Here, we evaluate MOR-1K in the development of OIH using three genetically diverse 
mouse strains alongside small interfering RNA (siRNA) knockdown of MOR-1K. Our results 
demonstrate that OIH is associated with increased MOR-1K gene expression levels in a strain-specific 
manner. Disrupting the increase in MOR-1K gene expression levels via chronic intrathecal (i.t.) 
siRNA administration not only hinders the development of OIH, but also increases morphine 
analgesic efficacy. Collectively, these findings demonstrate that MOR-1K is likely a key contributor 
to OIH.  
2.2. Materials and Methods 
2.2.1. Ethical Statement 
All procedures within this study were approved by the University of North Carolina Animal 
Care and Use Committee (permit number: 12-319) and adhered to the guidelines of the Committee for 
Research and Ethical Issues of the International Association of the Study of Pain (http://www.iasp-
pain.org/Education/Content.aspx?ItemNumber=1217). All surgeries were performed under 
isofluorane anesthesia, and all efforts were made to minimize suffering.  
2.2.2. Animals 
Male and female C57BL/6J (http://jaxmice.jax.org/strain/000664.html) and CXB7/ByJ 
(http://jaxmice.jax.org/strain/000357.html) mice were obtained from Jackson Labs (Bar Harbor, ME) 
while 129S6 (http://www.taconic.com/129SVE) mice were obtained from Taconic (Germantown, 
NY). All mice were 8 -12 weeks old, weighed 20-30 g, were maintained under 12-hour light/dark 
cycle, and were fed ad libitum.  
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2.2.3. Drugs and Chemicals 
Morphine sulfate (Sigma, MO) was dissolved in 0.9% sterile saline (Hospira, IL). Doses of 
10 mg/kg, 20 mg/kg, or 40 mg/kg were administered via subcutaneous (s.c.) injection in a volume 
determined by animal weight (1µl/g). Fluorescein-tagged exon 13-antisense siRNA [5’-UCA GUC 
UUU AUC AGC UCA CCG CCA-3’] or fluorescein-tagged exon 13-sense siRNA (Midland Certified 
Reagent Co., OH)  [5’-AGU CAG AAA UAG UCG AGU GGC GGU-3’] in artificial cerebrospinal 
fluid was administered at a rate of 0.5μl/hr; 0.291μg/hr/day for a duration of 7 days via Alzet osmotic 
mini-pump (Durect, CA) connected to an i.t. catheter (Durect, CA). Previous studies have 
successfully administered siRNA in this fashion as well (131,132). Sense siRNA was chosen as a 
negative control as it is related to the target mRNA sequence of interest but does not affect target 
mRNA expression (133). 
2.2.4. Experimental Design 
Experiment 1: The effects of chronic morphine administration on pain behavior and gene 
expression.  
Prior to chronic morphine administration, C57BL/6J, CXB7/ByJ, and 129S6 mice (N=96; 8 
males and 8 females per experimental condition) were assessed for baseline responses to mechanical 
and thermal heat stimuli. Following baseline assessments, mice received morphine similar to the 
murine OIH protocol described by Liang et al (37). Briefly, mice received vehicle (sterile saline) or 
escalating doses of morphine (10 mg/kg, 20 mg/kg, 20 mg/kg, and 40 mg/kg) twice daily (8am and 
6pm) via s.c. injection on days 1, 2, 3, and 4, respectively. Behavioral responses were evaluated prior 
to and immediately following the 8am injection on days 1-4 and at 8am on days 5-7. Gene expression 
levels were measured in tissues collected from separate groups of C57BL/6J, 129S6, and CXB7/ByJ 
mice (N=84; 3-4 males and 3-4 females per experimental condition) sacrificed on day 0, on days 1 or 
4 following the 8am injection, or on day 5 at 8am. The experimental design is illustrated in Figure 2A.  
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Experiment 2: The effects of MOR-1K exon 13 siRNA knockdown on OIH and MOR-1K gene 
expression.  
Prior to chronic morphine administration, CXB7/ByJ mice (N=48; 8 males and 8 females per 
experimental condition) were assessed for baseline responses to mechanical stimuli. Following 
baseline assessments, mice underwent surgery for chronic i.t. administration of antisense exon 13 
siRNA or sense exon 13 siRNA. Mice were anesthetized with 5% isofluorane and maintained at 2-3% 
isofluorane during i.t. catheter implantation, modified from Yaksh and Rudy protocol (134). A 
separate group of mice also underwent surgery for a sham procedure. The sham procedure, involving 
skin incision and muscle dissection without breakage of the arachnoid membrane to cause leakage of 
cerebral spinal fluid, was deemed appropriate to control for any postoperative pain. One day 
following surgery, mice from antisense, sense, and sham conditions began to receive either vehicle 
(sterile saline) or escalating doses of morphine as described above. MOR-1K gene expression levels 
were measured in tissues collected from separate groups of CXB7/ByJ mice (N=84; 3-4 males and 3-
4 females per experimental condition) sacrificed on day 0, on days 1 or 4 following the 8am injection, 
or on day 5 at 8am. The experimental design is illustrated in Figure 3A.  
2.2.5. Behavior 
Assessment of Paw Withdrawal Threshold, Mechanical Allodynia, and Mechanical 
Hyperalgesia 
Mice were handled and habituated to the testing environment for 4 days prior to baseline 
assessments. On test days, mice were placed in plexiglass cages positioned over an elevated wire 
mesh platform and habituated to the environment for 20 minutes. Paw withdrawal threshold in 
response to a series of 9 von Frey filaments (with bending forces of 0.03, 0.07, 0.17, 0.40, 0.70, 1.19, 
1.50, 2.05, 3.63g; Stoeling, IL) was assessed using the “up-down” method (135), starting with a 
filament with bending force of 0.70 g. In the absence of a paw withdrawal response, an incrementally 
stronger filament was presented and in the event of a paw withdrawal, an incrementally weaker 
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filament was presented. After the initial response threshold was crossed, this procedure was repeated 
in order to obtain a total of six responses in the immediate vicinity of the threshold. The pattern of 
withdrawals and absence of withdrawals were noted together with the terminal filament used in the 
series of six responses. The 50% of the paw withdrawal threshold is calculated as (10[Xf+
kδ])/10,000, 
where Xf = value (in log units) of the final von Frey hair used; k = tabular value of pattern of positive 
(X) and negative (O) responses, and δ = mean difference (in log units) between stimuli. Mechanical 
allodynia was assessed by presenting a filament with bending force of 0.40 g to the hind paw 10 times 
for a duration of 1 s with an inter-stimulus interval of 1 s. A significant increase in the percentage 
frequency of paw withdrawal ([# of paw withdrawals/10] x 100) was defined as mechanical allodynia. 
Mechanical hyperalgesia was assessed in the same manner, using a filament with a bending force of 
1.50 g.  
Assessment of Thermal Heat Hyperalgesia 
Thermal heat hyperalgesia was evaluated using the hot plate method (136). Mice were placed 
on a hot plate (Columbus Instruments, OH) maintained at a temperature of 51.5°C for one minute.  
Each session was videotaped and the total number of aversive responses (paw licks, paw flicks, and 
jumps) was measured.  
2.2.6. Assessment of Gene Expression Levels 
Discrete brain and spinal cord samples were collected on days 0, on day 1 and 4 following the 
8am morphine administration, and on day 5, 24 hours following morphine cessation. Total RNA from 
discrete brain regions (medulla, pons, periaqueductal grey, thalamus, hypothalamus, striatum, nucleus 
accumbens, and frontal lobe), and spinal cord was purified using 1mL TRIzol (Life Technologies, 
NY) for each tissue sample. Samples were immediately homogenized using a Pro200 homogenizer 
(Pro Scientific, CT) or Precellys 24 Homogenizer (Bertin Technologies, France) and all subsequent 
RNA purification steps were performed according to the TRIzol manufacturer recommendations. 
Purified RNA samples were treated with TURBO DNA-free (Life Technologies, NY) per 
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manufacturer protocol and concentrations were determined using a Nanodrop-1000 (Thermo 
Scientific, DE) and reverse transcribed using Transcriptor First Strand cDNA Synthesis kit (Roche, 
Switzerland) where necessary. Fast Start Universal SYBR Green Master with Rox (Roche, 
Switzerland) or Power SYBR Green RNA-to-CT 1-Step (Life Technologies, NY) were respectively 
used per manufacturer protocols to amplify cDNA and RNA, per manufacturer protocols. A 7900HT 
Fast Real-Time PCR system (Life Technologies, NY) and a StepOnePlus Real-Time PCR system 
(Life Technologies, NY) were respectively used for measuring cDNA or RNA transcripts 
amplification. The following primers were used for the detection of the following exon-11 containing 
MOR-1 splice variants: MOR-1K forward (TCCCCTCTTGAGTGTGACTAATGTC) and reverse 
(GCCAGAGCAAGGTTGAAAATG); MOR-1L forward 
(CAGAGCAAGGTTGAAAATGTAGATG) and reverse 
(AAATCAAAATAGAAAATGGGCTAAGG); MOR-1T forward 
(GAGCCACATGGAATTGCCTCTGTA) and reverse (GCATCTGCCAGAGCAAGGTTGAAA); 
forward (GGGCCGATGATGGAAGCTTTCTCTAA) and reverse 
(GCATCTGCCAGAGCAAGGTTGAAA) primers for splice variants that contain exons 11 and 2. 
Expression of the target genes was normalized to housekeeping genes RPL7 [forward 
(TCAATGGAGTAAGCCCAAAG) and reverse (CAAGAGACCGAGCAATCAA)] or GAPDH 
[forward (TGAAGGTCGGAGTCAACGGATTTGGT) and reverse 
(CATGTGGGCCATGAGGTCCACCAC)] using the 2(-ΔΔCT) method. All primers were purchased 
from Integrated DNA Technologies (CA). 
2.2.7. Statistical Analysis  
Baseline responses for paw withdrawal threshold, mechanical allodynia, and mechanical 
hyperalgesia for each strain were analyzed using one-way ANOVA followed by Bonferroni 
correction. Subsequent behavioral responses following morphine administration were then analyzed 
using two-way repeated measures ANOVA with Bonferroni correction for multiple comparisons. 
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Gene expression was analyzed using a linear mixed model, where the log (10) gene expression of 
each tissue-replicate assay was the dependent variable and strain was the random effect. For all tests, 
the criterion for statistical significance level was p<0.05. Statistical analyses were performed using 
Prism (GraphPad Software, CA) 
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2.3. Results 
2.3.1. Strains demonstrate divergent baseline pain profiles. 
First, we sought to establish baseline pain responses to mechanical stimuli in C57BL/6J, 
129S6, and CXB7/ByJ mice. The C57BL/6J strain was chosen as it is the most studied classic inbred 
strain, the 129S6 strain was chosen because of its reported resistance to opioid tolerance (137), and 
the CXB7/ByJ strain was chosen because of its reported decrease in MOR-1 gene expression (138). 
For all three strains, male and female mice demonstrated similar behavioral differences to mechanical 
and thermal heat stimuli (Figure 2.1); hence all behavioral data was pooled together for analysis.  
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Figure 2.1. Sex-dependent responses to mechanical and thermal heat stimuli across the three 
strains. Overall, males and females displayed similar behavioral responses to mechanical and thermal 
heat stimuli within strains. Female C57BL/6J mice demonstrated (A) increased paw withdrawal 
threshold (F(9,140) = 12.20, p<0.0001) and (B) increased responses following repeated exposure to an 
innocuous mechanical stimulus (F(9,140) = 14.50, p<0.0001). Panels A-D: N=7-8/group. Males are 
represented in black bars while females are represented by white bars. Data expressed as mean ± 
SEM.****p<0.0001, ***p<0.001, *p<0.05 different from males.   
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Our results showed that the strains exhibited baseline differences in mechanical (Figure 2.2A, 
F(2,43)=20.56, p<0.0001; Figure 2.2B, F(2,43)=43.77, p<0.0001), and thermal heat pain sensitivity 
(Figure 2.2C; F(2,43=10.64, p=0.0002). Compared to the classic C57BL/6J inbred strain, 129S6 mice 
were less pain sensitive, exhibiting higher paw withdrawal thresholds and fewer responses to a 
noxious mechanical stimulus or to thermal heat. In contrast, CXB7/ByJ mice were more pain 
sensitive, exhibiting lower paw withdrawal thresholds and increased responses to innocuous 
mechanical or thermal heat stimuli.  
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Figure 2.2. Strains exhibit divergent behavioral responses to mechanical stimuli at baseline 
Compared to C57BL/6J mice, 129S6, and CXB7/ByJ mice exhibit differences in (A) paw withdrawal 
threshold, (B) the number of responses to repeated presentation of a noxious mechanical stimulus 
sensitivity, and (C) the number of responses to continuous thermal heat. N=15-16/group. Data 
expressed as mean ± SEM. ***p<0.001, **p<0.01, *p<0.05 different from C57BL/6J. ###p<0.001 
different from 129S6. 
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2.3.2. Strains demonstrate divergent pain profiles in a chronic morphine administration paradigm. 
Next, we sought to examine the strains’ pain responses following morphine administration 
using a modified murine paradigm for OIH (37). We assessed behavioral responses to mechanical and 
thermal heat stimuli on days 1-4 during chronic morphine administration and after morphine cessation 
on days 5-7 (Figure 2.3-2.4). When examining percent change from baseline responses, C57BL/6J, 
129S6, and CXB7/ByJ mice exhibited differences in paw withdrawal thresholds over time (Fig. 2.4B; 
F(18,430)=45.38, p<0.0001). C57BL/6J mice showed robust analgesia following morphine 
administration on days 1-4, then developed allodynia on day 4 prior to morphine administration and 
on days 5 and 6 following morphine cessation. When compared to C57BL/6J mice, 129S6 mice also 
showed analgesia following morphine administration on days 1-4, albeit to a lesser degree than 
C57BL/6J mice, however failed to develop allodynia at later time points (p<0.001). In contrast, 
CXB7/ByJ mice failed to show analgesia following morphine administration on days 1-4, but did 
develop allodynia prior to morphine administration on days 3 and 4 and following morphine cessation 
on days 5 and 6 (p<0.001). Of note, CXB7/ByJ mice also exhibited allodynia following morphine 
administration on day 3 (p<0.001).  
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Figure 2.3. Raw data illustrating behavioral responses of 129S6, C57BL/6J, and CXB7/ByJ 
mice to mechanical and thermal heat stimuli during chronic morphine administration. All three 
strains exhibit distinct behavioral differences in (A) paw withdrawal threshold (F(22,516) = 71.94, 
p<0.0001, and when assessing responses to the repeated exposure of (B)  an innocuous mechanical 
stimulus (F(22,516) = 35.37, p<0.0001), (C) a noxious mechanical stimulus (F(22,516) = 28.54, p<0.0001), 
and (D) a thermal heat stimulus; F(22,516) = 4.214, p<0.0001). Panels A-D: N=15-16/group. Data 
expressed as mean ± SEM. * = different from baseline. 
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Figure 2.4. Strains exhibit divergent morphine-dependent analgesic and allodynic/hyperalgesic 
profiles.  (A) A timeline of chronic morphine administration and the assessments of pain behavior 
and gene expression are shown. (B-E) Compared to C57BL/6J, 129S6 mice exhibit increased paw 
withdrawal thresholds and fail to develop allodynia or hyperalgesia. In contrast, CXB7/ByJ exhibit 
decreased paw withdrawal thresholds and increased allodynia and hyperalgesia. For behavioral 
graphs, blue background indicates a decrease in pain sensitivity (analgesia), and red background 
indicates an increase in pain sensitivity (allodynia/hyperalgesia). Panels B-D: N=15-16/group. Data 
expressed as mean ± SEM. ***p<0.001, **p<0.01, *p<0.05 different from C57BL/6J. ### p<0.001, 
##p<0.01, #p<0.05 different from 129S6. Panel E: N=7/group. Data expressed as means ± SEM. 
*p<0.05 different from baseline. 
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Strains also exhibited differences in their response to repeated presentation of a normally 
innocuous punctate mechanical stimulus over time (Fig. 2.4C; F(18,430)=32.88, p<0.0001). C57BL/6J 
mice developed mechanical allodynia prior to morphine administration on day 4 and following 
morphine cessation on days 5 and 6. Consistent with the paw withdrawal threshold data, 129S6 mice 
failed to develop mechanical allodynia. CXB7/ByJ mice, however, demonstrated the highest degree 
of mechanical allodynia, evident prior to morphine administration on days 3 and 4 and following 
morphine cessation on days 5-7 (p<0.001). 
Similarly, strains exhibited differences in their response to repeated presentation of a 
normally noxious punctate mechanical stimulus over time (Fig. 2.4D; F(18,430)=15.19, p<0.0001). 
C57BL/6J mice showed analgesia following morphine administration on days 1-4, then developed 
mechanical hyperalgesia prior to morphine administration on days 3 and 4 as well as following 
morphine cessation on days 5-7. 129S6 mice exhibited analgesia following morphine administration 
on days 1-4 (p<0.001), however failed to develop mechanical hyperalgesia at later time points. In 
contrast to the other strains, CXB7/ByJ mice failed to show analgesia following morphine 
administration, but did develop mechanical hyperalgesia prior to morphine administration on days 3 
and 4 as well as following morphine cessation on days 5 and 6 (p<0.001). Consistent with their 
changes in mechanical allodynia, CXB7/ByJ mice also exhibited mechanical hyperalgesia following 
morphine administration on day 3 (p<0.001). When assessed for behavioral responses to mechanical 
stimuli, saline treated controls did not exhibit any changes in paw withdrawal threshold or 
demonstrate mechanical allodynia or hyperalgesia (Figure 2.5). 
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Figure 2.5. Raw data illustrating behavioral responses of 129S6, C57BL/6J, and CXB7/ByJ 
mice to mechanical and thermal heat stimuli during saline administration. Strains exhibit no 
significant changes from their respective baselines when assessing for (A) paw withdrawal threshold 
(F(2,516) = 377.7, p<0.0001), and when assessing responses following repeated exposure to (B) an 
innocuous (F(2,516) = 29.08, p<0.0001), or (C) noxious mechanical stimulus (F(2,516) = 1857, p<0.0001). 
(D) Unlike 129S6 and C57BL/6J mice, CXB7/ByJ mice exhibited increased responses to thermal heat 
stimuli (F(2,516) = 115.2, p<0.0001) starting on day 1 following saline administration that steadily 
returned to baseline throughout testing. Panels A-D: N=15-16/group. Data expressed as mean ± SEM. 
* = different from baseline. 
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Finally, strains differed over time with respect to their response to thermal heat (Fig. 2.4E; 
F(18,430)=3.906, p<0.0001). When compared to 129S6 mice, C57BL/6J mice developed thermal heat 
hyperalgesia starting on day 2 prior morphine administration and following morphine cessation 
(p<0.001). CXB7/ByJ mice also developed develop thermal heat hyperalgesia on day 2 and 4 prior to 
morphine administration and following morphine cessation.  
3.3.3. MOR-1K gene expression levels parallel OIH profiles. 
To determine the relationship between OIH pain profiles and MOR-1K gene expression, 
spinal cord and discrete brain tissues were collected from separate groups of mice at times points 
corresponding to maximal analgesia and hyperalgesia. Changes in MOR-1K gene expression levels 
across the discrete brain and spinal cord tissues were not significantly different, and thus were 
normalized and pooled together (Figures 2.6-2.8). C57BL/6J, 129S6, and CXB7/ByJ mice exhibited 
divergent MOR-1K gene expression levels that paralleled their behavioral profiles (Figure 2.9; 
p=0.011). Compared to C57BL/6J mice, 129S6 mice demonstrated decreased MOR-1K gene 
expression levels on days 1 and 4 (p<0.05), in line with their analgesic responses. In contrast, 
CXB7/ByJ mice demonstrated increased MOR-1K gene expression levels on day 4 (p<0.05), in line 
with their hyperalgesic responses. Interestingly, MOR-1K gene expression levels for both 129S6 and 
CXB7/ByJ mice returned to near-baseline levels following the cessation of morphine treatment on 
day 5, suggesting that the observed differences were indeed morphine-dependent. To determine the 
potential involvement of other MOR-1 splice variants, we measured gene expression levels of other 
exon-11 containing splice variants (MOR-1G, MOR-1H, MOR-1I, MOR-1J, MOR-1L, MOR-1M, 
MOR-1N and MOR-1T). The splice variants did not exhibit significant changes in gene expression 
levels due to morphine administration (Figure 2.10.). 
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Figure 2.6. Z-scores of MOR-1K gene expression levels in discrete tissues of 129S6 mice. Tissue 
samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E) thalamus, (F) 
hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have similar MOR-1K gene 
expression levels in 129S6 mice. Panels A-I: N=7/group. Data expressed as Z-score. 
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Figure 2.7. Z-scores of MOR-1K gene expression levels in discrete tissues of C57BL/6J mice. 
Tissue samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E) thalamus, 
(F) hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have similar MOR-1K -
gene expression levels in C57BL/6J mice.  Panels A-I: N=7/group. Data expressed as Z-score 
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Figure 2.8. Z-scores of MOR-1K gene expression levels in discrete tissues of CXB7/ByJ mice. 
Tissue samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E) thalamus, 
(F) hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have similar MOR-1K -
gene expression levels in CXB7/ByJ mice. Panels A-I: N=7/group. Data expressed as Z-score. 
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Figure 2.9. Strains exhibit divergent MOR-1K gene expression levels that correspond to 
behavior profiles. 129S6 mice exhibit decreased MOR-1K gene expression levels on days 1 and 4, 
corresponding to their analgesic behavioral profile. In contrast, CXB7/ByJ mice exhibit increased 
MOR-1K gene expression levels on day 4, corresponding to their hyperalgesic behavioral profile. 
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Figure 2.10. Relative quantification of other exon 11 MOR-1 splice variants. (A-C). Chronic 
morphine administration does not significantly alter the gene expression levels of MOR-1 splice 
variants that contain exon 11, exon 14, or exon 16. Panels A-I: N=7-8/group. Data expressed as Z-
score. 
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2.3.4. Sustained delivery of MOR-1K exon 13 antisense siRNA prevents OIH. 
The observed correlation between strain-specific pain profiles and MOR-1K gene expression 
levels suggests that MOR-1K contributes to OIH in genetically susceptible mice. To determine 
whether MOR-1K is required for the development of OIH in CXB7/ByJ mice, we employed siRNA 
knockdown. Male and female CXB7/ByJ mice demonstrated similar behavioral phenotypes (Figure 
2.11.); thus, all behavioral data was pooled together for analysis. Within the OIH murine paradigm, 
we found that sustained i.t. delivery of exon 13 antisense siRNA prevented the development of 
mechanical allodynia (Figure 2.12B; F(2,189) = 24.69, p<0.0001, Fig. 2.12C; F(2,189) = 37.63, p<0.0001) 
and mechanical hyperalgesia (Fig. 2.12D; F(2,189)= 54.92, p<0.0001). In contrast, sustained 
administration of exon 13 sense siRNA or sham surgery did not prevent the development of 
mechanical pain sensitivity. Of note, we also found that sustained i.t. delivery of the antisense siRNA 
unmasked morphine analgesia in CXB7/ByJ mice not observed in sense and sham mice or saline-
treated controls (Figures 2.13-2.14.) A possible concern with sustained i.t. delivery is the 
development of inflammation and gliosis in the spinal cord in proximity with the catheter tip 
(139,140), and its effects on behavioral assessment. Given that CXB7/ByJ mice receiving sense 
siRNA and sham surgery displayed similar behavioral responses throughout testing, we believe that 
the use of i.t. catheters for sustained siRNA delivery did not impact the behavioral assessment of OIH.  
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Figure 2.11. Sex-dependent behavioral responses to mechanical stimuli across Antisense, Sense, 
and Sham mice. Male and female Antisense mice (A-C), Sense mice (D-F), and Sham mice (G-I) 
exhibited similar responses to mechanical stimuli within their respective treatment groups. Panels A-
I: N=3-4/group. Data expressed as mean ± SEM. 
  
 72
 
  
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-200
0
200
400
600
800
P
a
w
 W
it
h
d
ra
w
a
l T
h
re
s
h
o
ld
 
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
allodynia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-200
-100
0
100
200
300
400
P
a
w
 W
it
h
d
ra
w
a
l T
h
re
s
h
o
ld
 
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-150
-100
-50
0
50
100
P
a
w
 W
it
h
d
ra
w
a
l T
h
re
s
h
o
ld
 
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-150
-100
-50
0
50
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
allodynia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-100
-50
0
50
100
150
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-100
-50
0
50
100
150
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-100
-50
0
50
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
allodynia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-100
-50
0
50
100
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
allodynia
analgesia
2 
pr
e
2 
po
st
3 
pr
e
3 
po
st
4 
pr
e
4 
po
st 5 6 7
-100
-50
0
50
100
150
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
s
e
s
(%
 C
h
a
n
g
e
 F
ro
m
 B
a
s
e
lin
e
)
Paw Withdrawal Threshold Mechanical Allodynia Mechanical Hyperalgesia
A
n
ti
s
e
n
s
e
S
e
n
s
e
S
h
a
m
A B C
FED
G H I
 73
Figure 2.12. CXB7/ByJ mice treated with exon 13 antisense siRNA fail to develop OIH. (A) A 
timeline of sustained i.t. siRNA delivery, chronic morphine administration, and assessments of pain 
behavior and gene expression is shown. CXB7/ByJ mice receiving antisense siRNA exhibit analgesia 
following morphine administration and cessation, and fail to exhibit (B) decreased paw withdrawal 
thresholds, or increased responses to (C) repeated presentation of an innocuous or (D) noxious 
mechanical stimulus. In contrast, mice receiving sense siRNA or sham exhibited analgesia following 
morphine administration, which was then followed by allodynia/hyperalgesia on days 5-7. Panels B-
D: N=6-9/group. Data expressed as mean ± SEM.****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 
different from Sham.. 
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Figure 2.13. Raw data illustrate behavioral responses of Antisense, Sense, and Sham mice to 
mechanical stimuli during chronic morphine administration. Antisense mice exhibit (A) lower 
paw withdrawal threshold, (B) decreased responses to repeated innocuous (C) and noxious stimuli 
when compared to Sense and Sham mice. Panels A-C: N=6-9/group. Data expressed as mean ± SEM. 
* = different from baseline. 
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Figure 2.14. Raw data illustrate behavioral responses of Antisense, Sense, and Sham mice to 
mechanical stimuli during saline administration. Antisense, Sense, and Sham mice did not exhibit 
behavioral differences from their respective baselines when assessing for (A) paw withdrawal 
threshold (F(2,160) = 34.87, p<0.0001), (B) mechanical allodynia (F(2,160) = 45.01, p<0.0001), (C) 
mechanical hyperalgesia (F(2,160) = 23.43, p<0.0001) during saline administration. Panels A-C: N=6-
9/group. Data expressed as mean ± SEM. * = different from baseline. 
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2.3.5. Sustained delivery of MOR-1K exon 13 antisense siRNA decreases MOR-1K gene expression 
levels. 
Finally, we evaluated the efficacy of chronic siRNA administration to suppress MOR-1K 
gene expression levels in CXB7/ByJ mice. Given that siRNA was administered intrathecally, we 
examined MOR-1K gene expression within the spinal cord. As predicted, sustained i.t. delivery of 
antisense siRNA prevented the increase of MOR-1K gene expression levels in the spinal cord (Figure 
2.15; F(1,11)= 29.05, p=0.0002). In contrast, sustained delivery of sense siRNA failed to block 
increases in MOR-1K gene expression levels. These findings suggest that MOR-1K located in spinal 
sites is necessary for the development of OIH.  
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Figure 2.15. Sustained administration of MOR-1K antisense siRNA reduces MOR-1K gene 
expression levels. CXB7/ByJ mice receiving antisense siRNA exhibit decreased MOR-1K gene 
expression levels in the spinal cord as compared to those receiving sense siRNA. For all behavioral 
graphs, blue background indicates a decrease in pain sensitivity (analgesia), and red background 
indicates an increase in pain sensitivity (allodynia/hyperalgesia). N=3-4/group. **p<0.01 different 
from Sense. 
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2.4. Conclusion 
Here, we provide the first evidence suggesting that in genetically susceptible animals, MOR-
1K contributes to the development of OIH. Compared to C57BL/6J and 129S6 mice, CXB7/ByJ mice 
exhibited the greatest degree of pain following morphine administration alongside increased MOR-1K 
gene expression levels. Reductions in MOR-1K gene expression via sustained delivery of antisense 
siRNA not only prevented OIH, but also unmasked morphine analgesia.  
The results of this study demonstrate the significance of genetic variability of the mu-opioid 
receptor in the development of OIH. Of the three mouse strains, CXB7/ByJ mice exclusively 
exhibited increased pain sensitivity, evident immediately following morphine administration. Their 
hyperalgesic pain profile also paralleled increased MOR-1K mRNA transcript levels. For this reason, 
we selected this strain to examine the effects of MOR-1K knockdown using antisense exon 13 siRNA. 
CXB7/ByJ mice receiving sustained i.t. delivery of antisense MOR-1K siRNA failed to develop OIH 
and instead exhibited morphine analgesia. Sustained delivery of antisense siRNA significantly 
reduced MOR-1K gene expression levels within the spinal cord. Given that i.t. delivery provides 
direct access to the spinal cord, we hypothesize that MOR-1K siRNA integrated into primary and 
secondary order neurons and cleaved MOR-1K mRNA transcripts, resulting in decreased MOR-1K 
gene expression levels. As a complement to this experiment, we also sought to determine if MOR-1K 
overexpression would induce morphine-induced hyperalgesia. Specifically, 129S6 mice, the pain-
resistant strain that failed to develop morphine-induced hyperalgesia, received direct i.t. injections of 
adeno-associated virus (AAV) containing canonical MOR-1K plasmid DNA (MOR-1K C) or a SNP 
containing MOR-1K plasmid DNA (MOR-1K T). Preliminary data demonstrated that when compared 
to mice that received no vector or empty vector, mice that received either version of MOR-1K 
exhibited increased mechanical allodynia and hyperalgesia during chronic morphine administration 
(Appendix 2.1.). 
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When examining MOR-1K gene expression levels in the three mouse strains, we found that 
C57BL/6J mice exhibited different gene expression patterns during chronic morphine administration 
when compared to CXB7/ByJ mice. On day 1, C57BL/6J MOR-1K gene expression levels were 
similar to those of the CXB-7/ByJ mice, but on day 4 their expression levels decreased 2.4% while 
those of the CXB-7/ByJ mice increased 2.5%. It is possible that MOR-1K gene expression is 
negatively regulated in C57BL/6J mice and that is why they exhibit opioid-induced hyperalgesia to a 
lesser degree than CXB7/ByJ mice. For example, Lu et al provide evidence of microRNA-103/107 
downregulation of mu opioid splice variant MOR-1A (141).  Further research is needed to investigate 
the possible strain-specific modulators of MOR-1K expression. 
In this study, we observed that, despite a return of MOR-1K gene expression to baseline 
levels, C57BL/6J and CXB7/ByJ mice continued to exhibit OIH following morphine cessation (Fig. 
2). This persistence of OIH following opioid cessation has also been observed in other preclinical and 
clinical studies. In mice, administration of antagonists against the 5-HT3 receptor (5HT3R) (142), N-
Methyl-D-aspartate receptor (NMDAR), melanocortin-1 receptor (MC1R) (143) alongside morphine 
or beta-2-adrenergic receptor (β2AR) (37) prevent the development of OIH. In addition, β2AR-
deficient mice fail to develop OIH(37). Clinical studies have also shown that administration the β2AR 
antagonist propranolol (38) or NMDAR antagonist ketamine (32,144) alongside the fast-acting opioid 
remifentanil hinders the development of OIH following opioid cessation. Collectively, these findings 
suggest that MOR-1K may interact with other receptors, including 5HT3R, NMDAR, MC1R, and 
β2AR, to initiate and maintain OIH.  
The study highlights the impact of MOR-1 splice variants in opioid and pain signaling. So far, 
there are currently thirty-four MOR-1 splice variants in mouse, and twenty splice variants in human 
(61), numbers which suggest a vast array for functional implications. MOR-1 splice variants other 
than MOR-1K have been shown to play modulatory roles in opioid signaling. For example, Liu et al 
have demonstrated that splice variant MOR-1D heterodimerizes with the gastrin-releasing peptide 
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receptor, resulting in signaling that promotes opioid-induced itch (108). Another MOR-1 splice 
variant, MOR-1G, has been shown to heterodimerize with the nociceptin receptor ORL-1 to provide a 
binding site for the novel opioid analgesic 3-iodobenzoyl-6β-naltrexamide (145). Along with 
modulating opioid analgesia and opioid-related side effects, MOR-1 splice variants have also been 
shown to stabilize the canonical receptor at the cell membrane (117). These findings demonstrate the 
influence of splice variants on pain modulation and canonical receptor function. Future research is 
needed in order to elucidate the functional characteristics of other unexplored MOR-1 splice variants.  
Our findings extend previous work examining the effects of genetic variability on opioid 
analgesia and hyperalgesia.  Results from other animal studies have demonstrated strain-specific 
opioid analgesia efficacy (146) and fentanyl-induced hyperalgesia (147). Likewise, results from 
human studies have demonstrated that functional variation in the MOR-1 gene locus regulates opioid 
responses. For example, the MOR-1 A118G gene polymorphism, which leads to reduced MOR 
signaling (148), is associated with reduced morphine efficacy (149). More recently, the MOR-1K 
rs563649 polymorphism, which results in increased MOR-1K translation efficiency, has been 
associated with increased pain sensitivity and blunted morphine efficacy (128). Combined, these 
results suggest that genetic susceptibility, particularly in the MOR-1 gene locus, contributes to 
diminished opioid efficacy and the development of OIH. 
In order to understand the mechanisms whereby MOR-1K contributes to OIH, its expression 
patterns and signaling profiles must be defined. At the tissue level, MOR-1K is expressed in 
astrocytes within the central nervous system and in perineurial cells within the peripheral nervous 
system (150), indicating possible influence of glial activation in OIH (151). We have also shown that 
MOR-1K mRNA is co-expressed with S100, suggesting that the receptor is expressed with satellite 
glial cells (Appendix 2.2). At the cellular level, MOR-1K is normally expressed intracellularly (65), 
where it may drive Gs-dependent increases in intracellular cAMP and calcium following active 
transport or passive diffusion of morphine across the cell membrane (152,153). In the presence of 
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β2AR, a GPCR also implicated in OIH (38). MOR-1K has been shown to relocate to the cellular 
membrane in vitro (154). Specifically, the authors utilized immunofluorescence to show that MOR-
1K and β2AR co-localize within the cell and that both receptors move to the cell membrane. These 
data suggest the two receptors interact with one another, perhaps by forming a heterodimer. More in 
vitro studies, such as co-immunoprecipitation, are necessary to determine if this is indeed the case. 
Although its gene expression and signaling profiles are somewhat established, knowledge on MOR-
1K protein expression is lacking and needs to be defined. Currently available molecular tools, 
however, are not selective enough to identify and isolate the MOR-1K protein. Future MOR-1K 
studies will benefit from the development of antibodies and ligands that specifically target this splice 
variant.  
In conclusion, the present study demonstrates a functional role for MOR-1K in a murine 
model of OIH. More work is required to determine MOR-1K’s downstream effectors and signaling 
mechanisms as well as to understand its contribution to individual variability in a more 
comprehensive set of opioid responses. Outcomes from present and future studies will help elucidate 
the neurobiological mechanisms that drive OIH and, in turn, will inform the development of more 
rational treatment strategies that alleviate clinical pain while reducing OIH risk.  
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CHAPTER 3: Determining the Functionality of Strain-specific Mu-opioid Receptor 
Polymorphisms  
3.1. Introduction 
When examining the manifestation of OIH in genetically diverse strains of mice, we 
demonstrated that the three strains demonstrated divergent pain responses following chronic 
morphine administration that also corresponded to MOR-1K gene transcript levels. Specifically, when 
compared to C57BL/6J, 129S6 mice were pain resistant with decreased MOR-1K transcript levels. In 
contrast, CXB7/ByJ mice were pain sensitive with increased MOR-1K transcript levels. We 
hypothesized that variability in behavioral and gene expression profiles result from strain-specific 
variability in the MOR-1 gene locus. To test this hypothesis, we examined OPRM1 sequences from 
C57BL/6J, 129S6, and CXB7/ByJ strains for possible strain-specific polymorphisms. Furthermore, 
we utilized bioinformatic databases and cAMP assays to determine the functional impact of 
polymorphic alleles. 
3.2. Materials and Methods 
3.2.1. DNA Extraction and Sequencing 
Total RNA from discrete brain regions (medulla, pons, periaqueductal grey, thalamus, 
hypothalamus, striatum, nucleus accumbens, and frontal lobe), and spinal cord was purified using 
1mL TRIzol (Life Technologies, NY) for each tissue sample. Samples were immediately 
homogenized using a Pro200 homogenizer (Pro Scientific, CT) or Precellys 24 Homogenizer (Bertin 
Technologies, France) and all subsequent RNA purification steps were performed according to the 
TRIzol manufacturer recommendations. Purified RNA samples were treated with TURBO DNA-free 
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(Life Technologies, NY) per manufacturer protocol and concentrations were determined using a 
Nanodrop-1000 (Thermo Scientific, DE) and reverse transcribed using Transcriptor First Strand 
cDNA Synthesis kit (Roche, Switzerland). Prepared cDNA samples were then amplified using 
Advantage® HF 2 PCR Kit per manufacturer protocol (Takara Bio USA, CA). Amplified cDNA was 
sequenced by Genewiz and analyzed using Sequencher 5.1 (Gene Codes Co., MI). Sample sequences 
were compared to OPRM1 mRNA sequence (NCBI: NM_001039652.1) and MOR-1K cDNA (NCBI: 
AF260309.1). 
3.2.2. Predicting Alterations to Transcription Factor Binding Sites. 
A recent genome-wide analysis study investigating the role of OPRM1 polymorphisms in 
pain in humans demonstrated that a single nucleotide polymorphism (SNP) rs563649 facilitated 
increased MOR-1K transcription. Given that the identified murine SNP is also located in exon 13, we 
sought to determine if it altered existing transcription factor binding sites in the region. Thus, 
JASPAR CORE database(155) and TFSearch database (Computational Biology Research Consortium, 
Japan) were used to assess for changes to existing transcription factor binding in MOR-1 and MOR-
1K cDNA. 
3.2.3. Cyclic AMP Assay 
HEK293 cells were transduced with pAAV2-ZsGreen viral vector containing canonical 
MOR-1K plasmid cDNA, MOR-1K plasmid cDNA containing an exon 13 SNP, or empty vector 
(Biowit Technologies, Shenzhen, China). The same pAAV2 virus used to express MOR-1K was also 
used to express MOR-1K in 129S6 mice (Chapter 4) and establishes continuity between both 
experiments. A separate group of Human Embryonic Kidney (HEK) 293 cells, MOR-1 cDNA was 
transfected using Fugene HD per manufacturer protocol (Promega, WI). After transduction or 
transfection, cells were plated into 384 well plates. The seeded plates were treated with morphine or 
vehicle for 30 min then cAMP levels were detected using HitHunter cAMP Assay for Biologics 
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(DiscoverX, CA) per manufacturer protocol. The cAMP levels were measured using Cytation5 Cell 
Imaging Mutli-Mode Reader (BioTek, VT). 
3.3. Results 
3.3.1. CXB7/ByJ OPRM1 transcripts contained strain-specific polymorphisms 
First, we sought to determine if there were any genetic differences between C57BL/6J, 129S6, 
and CXB7/ByJ cDNA transcripts. Sequencing of the strains’ sequences revealed two single 
nucleotide polymorphisms, specifically within the CXB7/ByJ transcript. The first polymorphism 
(Figure 4.1, Table 4.1) was an A  C nucleotide change at position 6788673, located in exon 1 of 
OPRM1 transcript. The SNP, already identified as rs8241991, is implicated in MOR-1 receptor 
function. Lee and colleagues found that rs8241991 altered transcription factor binding to the SP1 
binding site, resulting in reduced MOR-1 gene expression levels characteristic of CXB7/ByJ mice 
(138).  
The second polymorphism was a previously unidentified C T nucleotide change at position 
6679800, located in exon 13. Using JASPAR CORE and TFSearch databases, we found that the SNP 
is located in an enhancer box, or E-box, regulatory binding site. Due to its sequence, CANNTG, E-
box regulatory sequences are capable of being functionally distinct and recruit a variety of basic 
helix-loop-helix (bHLH) proteins (156). A particular class of bHLH proteins, hypoxia-inducible 
factor (HIF) proteins, are known modulators of inflammation and pain (157-159) that are influenced 
by opioid administration(160,161). Given the importance of the E-Box motif in the regulation of pain 
and opioid function, it is possible that this SNP could alter MOR-1K receptor activity.  
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Table 3.1. Strain-specific SNPs in OPRM1 gene.  
 
Rs Number Position Region Variant Transcript AA change Strain 
rs8241991 6788673  Exon A>C MOR-1 Aspartic acid 
to alanine 
CXB7/ByJ 
[cite] 
Not Listed 6679800 Exon C>T MOR-1K  CXB7/ByJ 
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Figure 3.1. Predicted functional effects of strain-specific polymorphisms.  MOR-1 cDNA 
sequences from 129S6, C57Bl/6J, and CXB-7/ByJ mice were compared. (A) CXB-7/ByJ mice 
possess  a strain-specific polymorphism located in the SP 1 binding region of exon 1 that results in 
reduced MOR-1 gene expression. (B) CXB-7/ByJ mice also possess a polymorphism at position 65, 
in which a T allele replaces the canonical C allele. Transcription factor databases predict that this 
polymorphism is located within an enhancer-box motif transcription-binding site within exon 13.  
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3.3.2. Functionality via cyclic AMP assay 
Next, we sought to determine if the T allele altered functionality of the MOR-1K receptor. 
Previous studies have shown that MOR-1K is coupled to the Gs protein and cells transfected with the 
receptor maintain cAMP levels following morphine administration (65,162). Thus, we used cAMP 
levels a measure of functional output. To determine potential functionality of the T allele, HEK293 
cells were transduced with the pAAV2-ZsGreen virus containing empty vector, the canonical MOR-
1K cDNA (MOR-1K C), or the SNP-containing MOR-1K cDNA (MOR-1K T). As a control, another 
set of cells were transfected with MOR-1 cDNA. Following transduction or transfection, cells were 
treated with varying concentrations of morphine and cAMP levels were measured. We found that, 
when compared to empty vector, cells transfected with MOR-1 cDNA exhibited a dose-dependent 
decrease in cAMP levels following morphine treatment. In contrast, cells transduced with either 
MOR-1K C or MOR-1K T cDNA exhibited a dose-dependent increase in cAMP levels following 
morphine treatment (Figure 3.2). 
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Figure 3.2. Cells expressing MOR-1K demonstrate increased cAMP levels following morphine 
treatment. . HEK 293 cells expressing MOR-1, MOR-1K C, MOR-1K T, or empty vector were 
treated with varying concentrations of morphine or vehicle and cAMP levels were measured. When 
compared to cells expressing empty vector, cells expressing MOR-1 demonstrated a dose-dependent 
decrease in cAMP levels. In contrast, cells expressing either MOR-1K C or MOR-1K T demonstrated 
a dose-dependent increase in cAMP levels. There was no significant difference found between the 
two MOR-1K groups. Data shown as mean ± SEM. N=2 in triplicate. 
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3.4. Conclusion 
Here, we examined the genetic sequences of C57BL/6J, 129S6, and CXB7/ByJ mice for 
strain-specific polymorphisms. We identified two polymorphisms, specifically in CXB7/ByJ mice. 
One of the polymorphisms was a previously discovered SNP located in exon 1, and was associated 
with reduced SP1 binding, resulting in decreased MOR-1 gene expression. The second polymorphism 
was an unknown SNP located in exon 13. Transcription factor bioinformatic databases indicated that 
the exon 13 SNP was located in E-box motif site, a regulatory sequence capable of impacting pain 
and opioid receptor function. In order to determine if this SNP was functional, we sought to 
determine if the MOR-1K SNP variant would alter cAMP levels. Subsequent assays revealed that 
cells transduced with the canonical or the SNP containing MOR-1K cDNA demonstrated increased 
cAMP levels, with no significant differences between the two groups.  
It is of interest that rs824199 is also present in C57BL/6J mice. This strain also demonstrated 
morphine induced hyperalgesia, but also demonstrated morphine analgesia. The fact that C57Bl/6J 
and CXB/ByJ mice exhibit different morphine-induced behavioral profiles while expressing the same 
polymorphism suggests C57BL/6J mice may have genetic compensatory mechanisms to maintain 
normal levels of MOR-1 expression. Such compensatory features could be expressed in intronic or 
non-coding regions of the OPRM1 gene. Full genomic sequencing of OPRM1 gene from the three 
strains would allow for a more thorough investigation of genetic polymorphism that impact MOR-1 
expression. 
Along with rs824199, our study found a previously unidentified SNP within exon 13 of 
OPRM1 gene. This finding resembles the identification of rs563649 in the human OPRM1 gene. 
Specifically, Shabalina and colleagues found that rs563649, also located with exon 13, was associated 
with increased pain sensitivity and blunted morphine efficacy in healthy individuals (128). The study 
also demonstrated that the polymorphism did not alter opioid receptor structure, but altered 
transcriptional regulation of the splice variant MOR-1K. Given the similar location of the 
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polymorphism in the OPRM1 gene, we sought to determine if the murine exon 13 SNP also had a 
functional impact on opioid analgesia as well. 
Although the MOR-1K SNP does not appear to alter cAMP function, it may still affect 
transcriptional regulation of MOR-1K receptor. In order to assess if the MOR-1K SNP alters 
transcriptional regulation, a luciferase assay may be utilized. Here, 5’ regions upstream of the MOR-
1K promoter, containing the canonical C allele or T allele, will be inserted into luciferase vectors and 
transfected into HEK293 cells. Transfected cells will be treated with morphine or vehicle, then 
assessed for differences in luminescence. The results of this study will inform if altered 
transcriptional regulation contributes to the CXB7/ByJ strain’s morphine-induced pain sensitivity. 
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CHAPTER 4: Discussion 
5.1. The importance of alternative splicing in pain  
Pain is a multidimensional system designed to protect organisms from harmful and dangerous 
environmental stimuli. Acute pain allows us not only to quickly respond to a noxious stimuli but also 
to learn to avoid such stimuli in the future, thus aiding in the adaptive learning process. Chronic pain, 
however, is maladaptive, persisting in the absence of noxious stimuli and interfering with normal 
homeostasis. For both categories of pain, it is important to understand the mechanisms for both types 
of pain in order to enhance our knowledge and provide solutions. 
G-protein coupled receptors (GPCRs) are key in pain transmission, regulation, and 
modulation. It is evidenced by the large amount of pharmacologic agents that directly target GPCRs 
for pain management. Because of this, a majority of pharmacologic agents used in acute and chronic 
pain treatment specifically target key GPCR families, including cannabinoid receptors, serotonergic 
receptors, alpha and beta adrenergic receptors, and opioid receptors. Although many of these drugs 
are considered clinical treatment standards, they are not without their faults; these drugs produce 
unwanted side effects and vary in efficacy depending of the individual patient. These unwanted 
results are partially due to unintended activation of GPCR splice variants. In order to develop 
enhanced treatments that provide better outcomes, it is essential to acknowledge that the alternative 
splice variants of these GPCR also contribute to pain management as well. 
Alternative splicing is a regulated genetic process in which a single gene can produce 
multiple distinct proteins. These proteins can be the result of exon skipping, 3’ or 5’ splice site 
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insertions, or intron retention. Alternative splicing greatly adds to the diversity of GPCRs by 
producing functional GPCR splice variants, especially those involved in pain transmission and 
modulation. The resulting receptors can have a variety of downstream consequences that can aid or 
attenuate analgesic treatments. An example showcasing the unforeseen impact of GPCR alternative 
splice variants on pain management is the role of MOR-1K in the development of opioid-induced 
hyperalgesia. 
5.2. Opioid induced hyperalgesia and MOR-1K 
Opioids are the most frequently used treatment for acute and chronic pain management. 
Unfortunately, opioid analgesia is coupled with unwanted side effects such as tolerance, respiratory 
depression, and addiction. Another unwanted side effect is the paradoxical increase in pain sensitivity 
known as opioid induced hyperalgesia (OIH). Preclinical research investigating OIH has shown that 
the disorder is due peripheral and spinal sensitization. Specifically, sustained opioid administration in 
rodents is associated to increased NMDA receptor activity, decreased glutamate reuptake, and 
increased glutamate release. Chronic opioid administration also evokes increased inputs from the 
descending facilitation system that results in increased spinal dynorphin levels. The culmination of 
these molecular changes lead to increase firing in pro-nociceptive neurons, leading to increased pain 
transmission and pain perception.  
Although the aforementioned mechanisms are key in producing OIH, it is still unclear which 
receptor is needed to initiate OIH. Given that opioids produce OIH, a mu opioid receptor/ a receptor 
activated by opioid binding and that also utilizes a excitatory signaling pathway is critical to drive 
OIH. For this reason, the alternative splice variant MOR-1K is very likely to be possible initiator of 
OIH.  
The splice variant MOR-1K is thought to play a role in OIH due to its genetic association to 
pain and its signaling profile. When investigating associations between pain and human mu opioid 
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related genes, Shabalina et al identified SNP rs563649 within exon 13 in OPRM1 transcript. 
Specifically, the authors found that individuals with this polymorphism exhibited higher pain 
sensitivity and blunted morphine efficacy (128). The study also showed that the SNP increased 
transcription of its splice variant, MOR-1K. A subsequent cellular study demonstrated that MOR-1K 
utilizes a excitatory signaling system. Cells transfected with MOR-1K did not reduce cAMP levels, 
increased intracellular calcium levels and in bound to the excitatory Gs protein(65). 
Given its genetic association to pain and its signaling profile, we next sought to determine if 
MOR-1K contributed to OIH in a genetic-dependent manner. To accomplish this, we used genetically 
diverse mouse strains: C57BL/6J, a common inbred strain; 129S6, a mouse strain resistant to opioid 
tolerance; and CXB7/ByJ, a mouse strain with reduced MOR-1 gene expression. Baseline assessment 
revealed that the strains had divergent pain response, such that 129S6 was the most pain resistant 
while CXB7 mice were the most pain sensitive. 
During chronic morphine administration, strains again demonstrated divergent pain responses 
to mechanical and thermal heat stimuli. C57BL/6J mice demonstrated increased morphine analgesia 
that was followed by increased pain sensitivity. 12S6 mice also demonstrated increased analgesia, but 
failed to develop any pain sensitivity. In contrast, CXB7/ByJ mice exclusively demonstrated 
increased pain sensitivity following morphine administration. The strains’ MOR-1K gene expression 
also corresponded with their pain profiles. The pain-resistant 129S6 mice demonstrated decreased 
MOR-1K gene expression during morphine administration while the pain sensitive CXB7/ByJ mice 
demonstrated increased MOR-1K gene expression. It is important to note that this is a morphine-
dependent effect, as the strains’ gene expression levels returned to their respective baseline levels on 
day 5. 
To further establish MOR-1K in OIH, we sought to determine the effects of MOR-1K gene 
knockdown in the pain sensitive CXB7/ByJ mice. MOR-1K gene knockdown was achieved via 
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chronic administration of exon 13 antisense siRNA. Sustained antisense siRNA administration not 
only hindered the development of morphine-induced hyperalgesia in CXB7/ByJ mice, but also 
unmasked morphine analgesia that was previously absent. 
5.4. The impact of murine MOR-1K polymorphisms on functionality 
The strain–specific behavioral and genetic divergences observed in chapter 3 lead us to inquire if 
these differences could be due to underlying genetic polymorphism. In order to test this hypothesis, 
we first sought to determine if there were an genetic polymorphisms between C57BL/6J, 129S6, and 
CXB7/ByJ mice. Sequencing of the strains’ OPRM1 mRNA transcripts revealed two SNP in 
CXB7/ByJ mice. The first SNP, identified as rs8241991, has been shown to reduced SP1 binding in 
exon 1, resulting in reduced MOR-1 gene expression(138). 
The second SNP discovered is a previously unknown C to T nucleotide change within exon 13. 
Given that exon 13 is distinct to MOR-1K, we next sought to determine if the presence of the exon 13 
SNP would have a functional consequence. Utilizing transcription factor binding site databases, we 
found that the exon 13 SNP is located in an E-box regulatory motif sequence, a binding site for many 
transcription factors including HIF-1. Given the implications of HIF-1 in pain and inflammation, it is 
possible that changes in the exon 13 E-box site may impact MOR-1K receptor function. 
In order to assess if the exon 13 SNP alters MOR-1K receptor activity, we assessed for changes in 
the cAMP levels of cells transduced with virus containing either the canonical MOR-1K transcript or 
the exon 13 SNP transcript following chronic morphine administration. We found that cells 
transduced with either variant of MOR-1K demonstrated a dose-dependent increase in cAMP levels 
but without significant differences within the two groups. Although no differences we found in cAMP 
levels, it is still possible that the exon 13 SNP may impact functionality in another fashion. Future 
experiments should focus examining if the SNP alters transcriptional regulation via a luciferase assay. 
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5.5. Future Directions 
The culmination of the presented work has cemented a foundation for the role of MOR-1K in 
the OIH development, and highlights the importance of GPCR alternative splice variants in pain 
management. Although the presented work provides a breadth of information about the splice variant 
MOR-1K, there is still much to learn in order to effectively combat opioid-induced hyperalgesia. For 
example, the work presented only studied animals received morphine in the absence of any injury or 
insult. This is contrary to what occurs clinically; those who are at risk of developing OIH take opioids 
because they suffer from acute or chronic pain. In order for the results to be more applicable to the 
clinical presentation of OIH, future preclinical investigations of OIH need to done within injury 
models. 
Second, it is necessary to better define MOR-1K’s signaling pathway. Gris et al have shown 
that BE2C cells transfected with MOR-1K bind to GS protein and are expressed intracellularly. One 
question that has yet to be answered is if MOR-1K signaling occurs intracellularly or at the 
membrane. Recent evidence from the Diatchenko lab suggests that MOR-1K may heterodimerize 
with another receptor in order to signal at the plasma membrane. Samoshkin et al have shown that 
MOR-1K forms a heterodimer with the beta 2-adrenergic receptor following morphine 
administration(163). Dever et al have also shown that cells co-transfected with MOR-1K and filamin 
A, a cytoskeletal protein, express the splice variant at the cell surface. These studies clearly show 
heterodimerization is necessary for MOR-1K movement to the plasma membrane. Future studies need 
to focus on demonstrating MOR-1K heterodimerization in mammalian tissue or in vivo. 
Future experiments also need to examine the relationship/interactions/duality between MOR-
1 and MOR-1K signaling. Given that opioids bind to both receptors, it is intriguing that OIH can 
develop with MOR-1 stimulation. It is essential to determine what happens to MOR-1 receptor 
availability and signaling during OIH and why MOR-1-induced analgesia does not balance out OIH. 
A recent study from the Taylor lab may shed some light as to way MOR-1 activation is not enough to 
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quell OIH. Corder and colleagues have shown MOR-1 remains constitutively active long after 
exposure to the initial injury (164). Blocking of this activity with naloxone increased pain sensitivity, 
suggesting that there is a delicate balance between lingering pronociceptive signaling and analgesia 
produced by MOR-1 constitutive activity. Given that opioid administration induces MOR-1 
intracellular translocation (165), it may be possible that an imbalance occurs with reduce MOR-1 
expression. This imbalance, combined with previously existing pronociceptive signaling and new 
MOR-1K signaling, may lead to the development of OIH in post-surgical patients (acute injury) and 
chronic pain patients (chronic injury).   
In line with examining MOR-1K signaling, it is also important to determine if all or specific 
opioids produce OIH. Thus far, morphine, DAMGO, fentanyl, sufentanil, remifentanil, and 
methadone have been shown to produce OIH in experimental or clinical settings (166). IBNtxA, a 
promising new analgesic that doesn’t produce respiratory depression, constipation, withdrawal, or 
addiction, also produces OIH(163). In order to develop more promising opioid therapeutics, it is 
essential to keep all the unwanted opioid side effect in mind.  The data within the present work 
supports this goal and will inform the development of more rational treatment strategies that alleviate 
clinical pain while reducing OIH risk. 
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APPENDIX 2.A.: A Preliminary Study Investigating Virally Mediated MOR-1K 
Overexpression in 129S6 Mice. 
Introduction 
In Chapter 2, we found that genetically diverse strains of mice demonstrated divergent 
behavioral responses and MOR-1K gene expression following chronic morphine administration. In 
particular, we found that the 129S6 strain was the most pain resistant, exhibiting morphine analgesia 
alongside decreased MOR-1K transcript levels. In contrast, the CXB7/ByJ strain was the most pain-
sensitive, exclusively exhibiting morphine-induced hyperalgesia alongside increased MOR-1K 
transcript levels. Furthermore, we found that sustained intrathecal administration of antisense exon 13 
siRNA prevented the development of morphine-induced hyperalgesia in the pain sensitive CXB7/ByJ 
mice. As a complement to the siRNA experiment, we next sought to determine if MOR-1K gene 
over-expression would facilitate the development of OIH in the pain-resistant 129S6 strain. The 
results from preliminary group of 129S6 suggest the virally directed MOR-1K overexpression 
produces morphine-induced hyperalgesia. Additionally, mice overexpressing MOR-1K demonstrated 
morphine-induced increases in glial reactivity and neuronal activation.  
Methods and Materials 
Ethical Statement 
All procedures within this study were approved by the Duke University Institutional Animal 
Care and Use Committee (protocol number: A010-16-01) and adhered to the guidelines of the 
Committee for Research and Ethical Issues of the International Association of the Study of Pain 
(http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1217). All surgeries were 
performed under isofluorane anesthesia, and all efforts were made to minimize suffering.  
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Animals 
Male and female 129S6 (http://www.taconic.com/129SVE) mice were obtained from Taconic 
(Germantown, NY). All mice were 8 -12 weeks old, weighed 20-30 g, were maintained under 12-hour 
light/dark cycle, and were fed ad libitum.  
Drugs and Chemicals 
Morphine sulfate (Sigma, MO) was dissolved in 0.9% sterile saline (Hospira, IL). Doses of 
10 mg/kg, 20 mg/kg, or 40 mg/kg were administered via subcutaneous (s.c.) injection in a volume 
determined by animal weight (1µl/g). A pAAV2-ZsGreen viral vector containing canonical MOR-1K 
plasmid DNA or MOR-1K plasmid cDNA containing an exon 13 SNP (Biowit Technologies, 
Shenzhen, China) was administered i.t. via direct injection.  
Experimental Design 
The effects of MOR-1K over-expression on the development of OIH 129S6 mice.  
Prior to chronic morphine administration, 129S6 mice (N=7; 3 males and 4 females) were 
assessed for baseline responses to mechanical and thermal heat stimuli. Following baseline 
assessments, mice underwent isoflurane anesthesia to receive direct i.t. injection of pAAV2-ZsGreen 
viral vector, viral vector containing canonical MOR-1K plasmid cDNA, or viral vector containing 
exon 13 SNP MOR-1K plasmid cDNA. Mice were anesthetized with 5% isofluorane and maintained 
at 2-3% isofluorane. One mouse did not receive direct injection of any substance. Two weeks were 
allowed for proper viral transduction into the spinal cord and dorsal root ganglion. Two weeks 
following initial direct injection, all mice were re-assessed for responses to mechanical and thermal 
heat stimuli. Following baseline assessment, mice began to receive escalating doses of morphine on 
days 1-4 as described above. Separate groups of 129S6 mice ((N=5; 3 males and 2 females)) were 
sacrificed on day 4 following the 8am injection. The experimental design is illustrated in Figure 
A2.A.1. 
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Figure A2.A.1. Timeline of the preliminary 129S6-MOR-1K overexpression experiment.  
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Behavior 
Assessment of Paw Withdrawal Threshold, Mechanical Allodynia, and Mechanical 
Hyperalgesia 
Mice were handled and habituated to the testing environment for 4 days prior to baseline 
assessments. On test days, mice were placed in plexiglass cages positioned over an elevated wire 
mesh platform and habituated to the environment for 20 minutes. Paw withdrawal threshold in 
response to a series of 9 von Frey filaments (with bending forces of 0.03, 0.07, 0.17, 0.40, 0.70, 1.19, 
1.50, 2.05, 3.63g; Stoeling, IL) was assessed using the “up-down” method (135), starting with a 
filament with bending force of 0.70 g. In the absence of a paw withdrawal response, an incrementally 
stronger filament was presented and in the event of a paw withdrawal, an incrementally weaker 
filament was presented. After the initial response threshold was crossed, this procedure was repeated 
in order to obtain a total of six responses in the immediate vicinity of the threshold. The pattern of 
withdrawals and absence of withdrawals were noted together with the terminal filament used in the 
series of six responses. The 50% of the paw withdrawal threshold is calculated as (10[Xf+
kδ])/10,000, 
where Xf = value (in log units) of the final von Frey hair used; k = tabular value of pattern of positive 
(X) and negative (O) responses, and δ = mean difference (in log units) between stimuli. Mechanical 
allodynia was assessed by presenting a filament with bending force of 0.40 g to the hind paw 10 times 
for a duration of 1 s with an inter-stimulus interval of 1 s. A significant increase in the percentage 
frequency of paw withdrawal ([# of paw withdrawals/10] x 100) was defined as mechanical allodynia. 
Mechanical hyperalgesia was assessed in the same manner, using a filament with a bending force of 
1.50 g.  
Assessment of Thermal Heat Hyperalgesia 
Thermal heat hyperalgesia was evaluated using the hot plate method (136). Mice were placed 
on a hot plate (Columbus Instruments, OH) maintained at a temperature of 51.5°C for one minute.  
Each session was videotaped and the total number of aversive responses (paw licks, paw flicks, and 
jumps) was measured.  
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Results 
pAAV2-Zsgreen is expressed in DRG 
Prior to conducting experiments, it was necessary to first establish that pAAV2-ZsGreen 
virus penetrated mouse spinal tissue. 129S6 mice were given a direct injection of pAAV2-Zsgreen 
empty vector to validate viral expression. Following two weeks, we found that the virus was robustly 
expressed in the DRG (Figure A2.A.2). With this information, we decided to proceed and examine if 
virally mediated MOR-1K overexpression would induce morphine-induced hyperalgesia in 129S6 
mice.  
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Figure A2.A.2. pAAV2-ZsGreen is expressed in 129S6 mouse dorsal root ganglion.  Following 
isoflurane anesthesia, 129S6 mice received an i.t. direct injection of 10uL of pAAV2-ZsGrean at L5 
of the spinal cord. The image was taken at 20X magnification. 
  
 110
 
  
 111
Viral vector mediated MOR-1K overexpression facilitates morphine-induced hyperalgesia 
We assessed behavioral responses to mechanical and thermal heat stimuli on prior to and two 
weeks following i.t. direct injection, on days 1-4 during chronic morphine administration, and after 
morphine cessation on days 5-7 When compared to mice that received empty vector or were untreated, 
129S6 mice that received either form of pAAV2-MOR-1K demonstrated decreased paw withdrawal 
threshold to mechanical stimuli (Figure A2.A.3A) starting on day 1 prior to morphine administration 
and continuing on day 2, 3, and 4 prior to morphine administration and following morphine cessation. 
Acutely following morphine administration, 129S6 mice exhibited morphine analgesia regardless of 
the treatment condition. It is interesting to note that mice that received the MOR-1K T variant 
exhibited reduced morphine analgesia on day 2, 3, and 4. 129S6 mice that received either form of 
pAAV2-MOR-1K also exhibited increased responses to a mechanical innocuous stimulus and a 
mechanical noxious stimulus prior to morphine administration (Figure A2.A.3B-C). These mice also 
demonstrated increased pain sensitivity to thermal heat stimuli prior to morphine administration 
(Figure A2.A.3D). Again, it is of note that 129S6 mice that received the MOR-1K T variant exhibited 
reduced morphine analgesia on days 2, 3, and 4 when assessing for mechanical allodynia and 
mechanical hyperalgesia. 
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Figure A2.A.3. Raw data illustrating behavioral responses of pAAV2-MOR1K 129S6 mice to 
mechanical and thermal heat stimuli during chronic morphine administration. When compared 
to mice that received empty vector or no vector, mice that received MOR-1K containing virus 
demonstrated (A) decreased mechanical paw withdrawal threshold (B) increased mechanical 
allodynia, (C) increased mechanical hyperalgesia and (D) thermal heat hyperalgesia following 
chronic morphine administration. Panels A-D: N=1-2/group. Data expressed as mean ± SEM.  
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Conclusions 
Here, in this preliminary study, we provide evidence that virally mediated overexpression of 
MOR-1K in 129S6 mice may produce morphine-induced hyperalgesia. Specifically, we show that 
129S6 mice that received direct i.t. injection of pAAV2 containing either canonical MOR-1K cDNA 
or SNP MOR-1K cDNA exhibited decreased mechanical paw withdrawal threshold, increased 
allodynia and hyperalgesia to mechanical stimuli, and increased hyperalgesia to thermal stimuli. To 
validate the findings in this preliminary study, the existing behavioral groups need to be expanded 
and a separate behavioral group, in which mice are treated with vehicle, needs to be added as well.  
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APPENDIX 2.B.: MOR-1K Localization using RNAscope® In Situ Hybridization 
Introduction 
In order to better understand how MOR-1K signaling contributes to OIH, it is necessary to 
first establish which cell types express the receptor. Here, we use in situ hybridization, in conjunction 
with immunohistochemistry, to identify where MOR-1K mRNA is expressed.  
Methods and Materials 
DRG samples were collected from 129S6 mice following cardiac perfusion with cold 0.1M 
PBS and 4% paraformaldehyde. Tissues were post-fixed overnight in 4% paraformaldehyde, then 
cryoprotected sequentially in 10% sucrose/0.1M PBS, 20% sucrose/0.1M PBS, and 30% 
sucrose/0.1M PBS for 24hrs in each solution at 4°C. The cryoprotected samples were set in Tissue-
Tek O.C.T. Compound (Sakura Finetek USA, CA), rapidly frozen in an ethanol/dry ice bath and 
stored in -80°. Transverse sections (10 μm) were cut using a Microm HM 550 cryostat (Thermo 
Fisher Scientific, MA) at. The following sections were placed on Superfrost Plus slides (Thermo 
Fisher Scientific, MA) and stored in -80C. Sections were pretreated and probed for positive control 
(Mm-Ppib), negative control (negative control probe_dapB), MOR-1K (Mm-Oprm1-MOR-1L-O1), 
or TRPV1 (Mm-Trpv1) as per the manufacturer’s protocol (Advanced Cell Diagnostics, CA). 
Following in situ hybridization, sections were rinsed in 0.01M PBS, then incubated for 30min in 
PBS-T. Sections were blocked in PBS-T containing 5% serum for 30 min, then immunolabeled using 
a primary antibody overnight. Primary antibody mouse monoclonal S100 (1:200, Abcam, MA) was 
used to stain for satellite glial cells. After several rinses in PBS-T, sections were incubated in 
biotinylated goat anti-mouse secondary antibody (Vector Laboratories, CA) for 2hrs. Sections were 
rinsed several times with PBS-T, and then incubated in VECASTAIN Elite Avidin-Biotin Complex 
solution (Vector Laboratories, CA) for 2hrs. Sections were rinsed in PBS-T, then incubated in 
ImmPACT SG Peroxidase HRP Substrate (Vector Laboratories, CA) to stain sections blue-gray. 
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Following several rinses in PBS-T, sections were dried at 60°C for 15 minutes and dipped in xylene. 
Coverslips were mounted to slides using EcoMount mounting medium (Biocare Medical, CA). 
Results 
Validation of RNAscope® Positive and Negative Controls 
Positive and negative control probes provided by the manufacturer were used to ensure that 
the protocol was performed appropriately. With the successful staining with the positive and negative 
controls (Figure A2.B.1), we next stained for MOR-1K and TRPV1 RNA. 
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Figure A2.B.1. Positive and negative control expression in mouse dorsal root ganglion.  DRG 
was treated with the (A) positive control probe, or (B) the negative control probe. The image was 
taken at 20x magnification.  
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MOR-1K RNA expression co-localizes with S100 expression 
Initial staining of DRG with MOR-1K RNA probe revealed a delicate, ring like expression 
surrounding cell bodies in the tissues (Figure A2.B.2). Subsequent histological investigations 
suggested the observed expression was similar to that of satellite glial cells (SGCs)(167). To confirm 
that MOR-1K RNA was expressed in SGCs, tissues were first treated with MOR-1K probe, then 
stained for S100, a marker of SGCs. Visualization of tissues incubated with both the MOR-1K probe 
and S100 demonstrated co-localization (Figure A2.B.3), suggesting that MOR-1K RNA is expressed 
in SGCs. 
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Figure A2.B.2. MOR-1K RNA expression in mouse dorsal root ganglion.  Mouse DRG tissue was 
treated with MOR-1K RNA probe and counterstained with hematoxylin. The image was taken at 20x 
and 40x magnification. 
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Figure A2.B.3. MOR-1K RNA expression co-localizes with S100 expression.  Mouse DRG tissue 
was incubated with MOR-1K RNA probe and S100 antibody. The image was taken at 20x and 40x 
magnification. 
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Figure A2.B.4. MOR-1K RNA expression in mouse dorsal root ganglion.  Mouse DRG tissue was 
treated with MOR-1K RNA probe and counterstained with hematoxylin. The image was taken at 20X 
magnification. 
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Conclusions 
Here, we demonstrate that MOR-1K RNA is expressed in satellite glial cells in DRG. Future 
research needs to expand MOR-1K localization and examine MOR-1K RNA expression in the spinal 
cord and in discrete brain regions. 
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